




Antidepressants in the perinatal period 


















































The studies described in this thesis were performed at the Department of Psychiatry, 
Erasmus Medical Center, Rotterdam, the Netherlands; the Department of Psychology, 
Utrecht University, Utrecht, the Netherlands; and the Department of Psychiatry, University 
of Amsterdam, Amsterdam, the Netherlands. 
 
Financial support for the publication of this thesis was kindly provided by the Erasmus 




Cover: Lorraine Jean Lauwerends 
Printed by: Ridderprint BV, Ridderkerk, the Netherlands 
 
Copyright Ó 2018 by Nina M. Molenaar. All rights reserved. For all articles published, 
the copyright has been transferred to the respective publisher. No part of this thesis may 
be reproduced, stored in a retrieval system or transmitted in any form or by any means, 
without the written permission of the author, or when appropriate, of the publishers of the 
publications. 
 
Antidepressants in the Perinatal Period 
challenging choices in current practice 
 
 
Antidepressiva tijdens de perinatale periode 







ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus 
 
Prof. dr. R.C.M.E. Engels 
 
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op 
 




Nina Maren Molenaar 
 












Promotoren: Prof. dr. W.J.G. Hoogendijk 
  Prof. dr. C.L.H. Bockting 
 
Overige leden: Prof. dr. V.J.M. Pop 
  Dr. B.C.P. Koch 
  Dr. I.M. van Vliet 
 
Copromotoren: Dr. M.P. Lambregtse-van den Berg 































Ch. 1 Introduction            7 
 
Part I. Perinatal use of antidepressants 
 
Ch. 2 Antidepressants: history and current use       23 
 
Ch. 3 Guidelines on treatment of perinatal depression with antidepressants:     31 
an international review 
 
Ch. 4 Antidepressants during pregnancy: guideline adherence and current    49 
practice amongst Dutch gynecologists and midwives 
 
Ch. 5 Dispensing patterns of selective serotonin reuptake inhibitors before,    69 
during and after pregnancy: a 16-year population-based Dutch cohort study 
 
Part II. The Stop or Go trial 
 
Ch. 6 Stop or Go? Preventive cognitive therapy with guided tapering of    91 
 antidepressants during pregnancy: study protocol of a pragmatic  
multicenter non-inferiority randomized controlled trial 
 
Ch. 7 Recurrence of depression in the perinatal period: Clinical features    111 
and risk factors in an observational cohort 
 
Part III. Impact of mental disorders during pregnancy on the offspring 
 
Ch. 8 Prenatal maternal psychopathology and stress and offspring HPA    133 
axis function at 6 years 
 
Ch. 9 General discussion        153 
 
 Summary         169 
 Nederlandse samenvatting        177 
 PhD portfolio         185 
 Curriculum Vitae         189 
 Dankwoord         193 












































































































Mental illness during the perinatal period is common and can affect both the mother and 
her unborn child. Especially perinatal depression, defined as depression arising in the 
period from conception to the end of the first postnatal year, is common, affecting up to 
12% of pregnant women (1). Additionally, women with a history of major depression are 
at increased risk for development of a depressive episode in the perinatal period (2). 
Prevention and management of mental illness in the perinatal period remains an area of 
discussion. Next to psychotherapy, administration of psychotropic medication is, 
according to clinical guidelines, a recommended treatment option (3). Among these, 
antidepressants are the most frequently prescribed psychotropic drugs during pregnancy 
(4), and selective serotonin reuptake inhibitors (SSRIs) in particular (5). However, 
treatment with antidepressant medication in the perinatal period has been under debate 
for the past decades. Researchers have been reporting conflicting results on the safety of 
antidepressants during pregnancy for the unborn child, leading to contradictory headlines 
in the media. 
 
 
- Antidepressants linked to premature birth - 
[The New York Times, April 7th 2014] 
 
- Relation between antidepressants and autism is wake-up call - 
[de Volkskrant, December 14th 2015] 
 
- Antidepressants during pregnancy are fine - 
[Algemeen Dagblad, January 24th 2016] 
 
- Good news about antidepressants in early pregnancy - 
[Futurity, April 19th 2017] 
 
- Using antidepressants during pregnancy may affect your child’s mental health - 
[ScienceDaily, September 7th 2017] 
 
- Taking antidepressants during pregnancy may lead to fetal brain changes - 







Depression and pregnancy 
Depression (major depressive disorder) is a serious mood disorder, characterized by 
either a depressed mood most of the day or a markedly diminished interest or pleasure in 
all, or almost all, activities most of the day, or both, for a minimal duration of two weeks. 
Additionally, people experience at least 3-4 of the following symptoms: significant weight 
loss or gain, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or 
loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished 
ability to think or concentrate or recurrent thoughts of death potentially with suicidal 
thoughts or attempts. Depression is a common mental disorder and the leading cause of 
disability worldwide (6). In high-income countries, up to 15% of people experience at least 
one major depressive episode in their life (7). Women in the Western world are affected 
twice as often as men (8). Pregnancy does not alter the risk of depression: it’s neither 
protective nor provocative. However, a depressive episode during pregnancy also 
involves the unborn child and treatment options may differ from those in a non-pregnant 
population. 
 
Potential risks of antidepressants during pregnancy 
There is much debate about the risks that antidepressants during pregnancy pose for the 
(unborn) child. An accumulation of studies has examined associations of antidepressant 
use during pregnancy with adverse child outcomes and the results of most of these studies 
have been aggregated in meta-analyses (9). Increased risks were observed for 
cardiovascular malformations (especially with paroxetine) (10), persistent pulmonary 
hypertension of the neonate (PPHN) (11), preterm delivery and lower birth weight (12) and 
psychiatric disorders in the offspring (e.g. mood disorders, autism spectrum disorder and 
behavioral disorder including attention deficit hyperactivity disorder) (13). These findings 
could not always be confirmed by other studies (14-17). A recent systematic review justly 
pointed out that verification of accurate and comparable between-group ascertainment is 
needed before definitive conclusions can be made (18). Even if the negative child 
outcomes are truly caused by antidepressants, the question remains how clinically 
important these findings are. For example, one study observed that exposure to 
antidepressants increased the risk of PPHN from 1.2 per 1000 liveborns to 3 per 1000 
liveborns (11). Although the risk is doubled, in absolute numbers the overall risk of PPHN 
after antidepressant exposure during pregnancy remains low. One could argue that, 
considering these low numbers, the benefits of treatment with antidepressants outweigh 






Potential risks of untreated mental illness during pregnancy 
Although antidepressant use during pregnancy might induce adverse child outcomes, 
untreated mental illness during pregnancy is not free of risk for the child either. Untreated 
maternal depression and anxiety has been associated with premature delivery and low 
birth weight (19-22). In the long-term, maternal mental illness during pregnancy increases 
the risk of behavioral, emotional, cognitive and motor problems in childhood (23-26) and 
psychiatric disorders in adolescence (27, 28). Research examining the origins of these 
increased risks led scientists to propose models such as the ‘fetal programming 
hypothesis’ (29) or the ‘developmental programming hypothesis’ (30, 31). According to 
these models, the fetus or infant makes adaptive responses to the health and physical state 
of the mother, thereby altering important physiological and metabolic processes that can 
endure into adulthood. The hypothalamic-pituitary-adrenal (HPA) axis is one of the major 
candidate systems that could be altered by adverse intrauterine exposures, especially since 
plasticity of the HPA axis is high during early fetal development (24, 32). The exact 
underlying mechanisms of HPA axis alteration in the offspring are still unclear, although 
previous studies have attempted to examine potential pathways involved. High levels of 
maternal cortisol reaching the fetus could either be the result of extreme maternal stress, 
overriding the capacity of placental 11ß-hydroxysteroid-dehydrogenase enzyme type 2 
(11ß-HSD-2) to convert cortisol into the inactive metabolite cortisone and thereby 
accumulating cortisol, or the result from altered expression of 11ß-HSD-2 in the placenta, 
as maternal psychopathology and stress during pregnancy have been associated with 
down regulation of 11ß-HSD-2, leading to active transfer of maternal cortisol into fetal 
circulation (33-35). Additionally, genetic factors and postnatal environmental factors such 
as parenting may play a role (36, 37). 
 
Knowledge gaps in current research 
The validity of findings can be questioned based on the limitations in research designs 
frequently used. Most of previously mentioned associations originate from retrospective 
observational studies with a lack to distinguish the effects of antidepressants from other 
shared risk factors, notably their indications depression and anxiety. Information on 
important confounders such as smoking behavior, socio-economic status, co-medication 
and co-morbidity are often not available. As a result, affected pregnant women and their 
health care professionals face complex decisions regarding initiation, continuation or 
discontinuation of antidepressants in the perinatal period. Questions often arise about the 
necessity and effectiveness of the medication during this specific period and about 
possible alternative treatment options. Although a significant number of women decide to 
discontinue antidepressants during pregnancy (38), to avoid potential damage to their 
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unborn child, no studies have examined the effectiveness of an alternative treatment option 
for pregnant women in which the antidepressant could be safely tapered without 
recurrence of depression. Therefore, in 2015 we started a randomized controlled trial 
(RCT) called Stop or Go, to study the safety and efficacy of preventive cognitive therapy 
with guided tapering of antidepressants during pregnancy. This national study was initiated 
from the Erasmus Medical Center, University of Utrecht and University Medical Center 
Groningen.  
 
Aims of this thesis 
Since much has already been written about the relation between antidepressants during 
pregnancy and increased risks in the offspring, the aim of this thesis is to evaluate 
translation of previous findings into current practice. We examine international differences 
in management of antidepressants during the perinatal period and observe the Dutch 
situation at greater detail. Additionally, we examine a clinical sample to identify risk factors 
for recurrence of depression in the perinatal period in women taking antidepressants. Last, 
we examine the influence of (untreated) symptoms of psychopathology and stress on child 
outcomes from a biological perspective.  
 
To that purpose the following research questions will be answered: 
1. What do internationally available guidelines recommend when it comes to 
treatment of perinatal depression and/or the perinatal use of antidepressants 
(chapter 3)? 
2. Are Dutch gynecologists and midwifes aware of the Dutch guideline on 
antidepressant use during pregnancy and do they adhere to this guideline 
(chapter 4)? 
3. In what way have Dutch perinatal dispensing patterns of antidepressants 
developed over time and to what extent was the introduction of the guideline of 
influence (chapter 5)? 
4. With what design can we examine the efficacy and safety of discontinuation of 
antidepressants during pregnancy (chapter 6)? 
5. Which women with antidepressant use during pregnancy have recurrence of 
depression in the perinatal period (chapter 7)? 
6. Is maternal psychopathology and stress during pregnancy associated with long-









Women that were included in the studies presented in this thesis originated from one of 
the following: 
 
1. The PHARMO-perined cohort: the PHARMO Database Network is a dynamic 
cohort of participants that includes, among other information, drug-dispensing 
records from community pharmacies for more than three million individuals in 
the Netherlands (approximately 25% of the Dutch population), collected since 
1998. Perined is a national registry that contains validated and linked data from 
four independent databases: the national obstetric database for midwives (LVR-
1), the national obstetric database for gynecologists (LVR-2), the national 
obstetric database for general practitioners (LVR-h) and the national 
neonatal/pediatric database (LNR). The registry contains information about care 
before, during and after delivery as well as maternal and neonatal characteristics 
and outcomes of 95% of 175.000 pregnancies annually in the Netherlands, with 
a minimal gestational age of 16 weeks. Linkage between the two databases is 
based on the birth dates of the mother and the child and their approximate 
address (39). We identified a cohort of 153,952 Dutch pregnancies from 1999 
to 2015 with data available on the 12-month period before conception and 12 
months after delivery.  
 
2. The Stop or Go study: both a Randomized Controlled Trial (RCT) and an 
observational cohort (2015-present) of women with antidepressant use at the start 
of their pregnancy. Women were recruited during their first prenatal visit in 
midwifery practices (first echelon care) and hospitals (second and third echelons 
care), through general practitioners (GPs) or through advertisement in (social) 
media. The recruitment network was built to reach women on a population level 
and consisted of 51 hospitals, of which eight were academic hospitals, and over 
120 midwifery practices. For recruitment through GPs, an alert was installed in 
Expertdoc (www.expertdoc.nl), an information system used by approximately two 
thirds of the GPs in the Netherlands. Further on, maximal effort was made to 
reach out to women in person; advertisement was placed in a magazine specific 
for women in their early pregnancy (Wij Zwanger, print circulation of 150.000) 
and on social media (facebook, instagram). Multiple newspaper articles were 
published drawing attention to the study and websites and forums posted calls 
to increase recruitment. Once recruited, experienced study researchers 
performed the counseling. Eligible for inclusion were women taking 
antidepressants at the start of their pregnancy. In the RCT, women were 
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randomized to either continuation of antidepressants during pregnancy or 
guided discontinuation of antidepressants with added preventive cognitive 
therapy during pregnancy. Women in the observational cohort made their own 
decision regarding continuation or discontinuation of antidepressants. The study 
did not provide treatment guidance to women in the observational cohort. 
Women and their children are followed until 5 years after delivery. As follow-up 
of the RCT has not yet been completed, this thesis will only report on outcomes 
of the observational cohort. However, the study protocol of the RCT will be 
discussed.  
 
3. The Generation R study: a population-based prospective cohort study. The study 
is designed to identify early environmental and genetic causes and causal 
pathways leading to normal and abnormal growth, development and health from 
fetal life, childhood and young adulthood. In total, n=8880 mothers were 
enrolled during pregnancy with deliveries from April 2002 to January 2006 (40). 
For this thesis, only mother-child couples that participated in the pre- and 
postnatal follow-up were considered. For analysis of long-term HPA axis activity, 
hair collection of the child at 6 years of age was required. Hair collection did 
not start immediately at onset of the Generation R data collection. Thus, n=2,546 
formed the study population for the current thesis. 
 
Outline of this thesis 
In Part I of this thesis we focus on treatment with antidepressants in the perinatal period. 
A general introduction on antidepressants is provided in chapter 2. The aim of this chapter 
is to gain insight in the history and development of the different types of antidepressants 
available and use of them in current society. In chapter 3 we present an international 
review on guidelines on treatment of perinatal depression with antidepressants. The aim 
of this study is to compare international guidelines to guide clinicians in best clinical 
practice. In chapter 4 we focus on the Dutch guideline on the use of antidepressants 
during pregnancy. Gynecologists and midwives throughout the Netherlands were 
questioned about the guideline and their adherence to it. We show guideline adherence 
among health care professionals and characteristics associated with adherence. The 
objective of chapter 5 is to assess perinatal dispensing patterns of antidepressants in the 
Netherlands over time. We use population-based information on medication dispensing 
and dispensing patterns over 16 years (1999-2015). We examine whether medication 
dispensing rates increase in accordance with trends observed in other developed 





The focus of Part II is the Stop or Go study. In chapter 6 we present the background for 
initiating this study and the protocol according to which this study (mainly the RCT) is 
performed. Outcomes of this RCT will not be reported in the current thesis. However, all 
measurements in the observational cohort were similar to the measurements in the RCT. In 
chapter 7 we therefore examine the first results from the observational cohort of Stop or 
Go. We aim to identify patient characteristics associated with depressive recurrence in the 
perinatal period.  
 
Part III of this thesis focuses on the influence of maternal mental illness during pregnancy, 
when not sufficiently treated, on child outcome from a biological perspective. In chapter 
8 we investigate the influence of maternal mental illness and stress on HPA axis activity in 
children 6 years of age using the Generation R cohort. Finally, in chapter 9 we discuss 
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A brief history of depression and antidepressants 
The history of depression is long, although over time it has been known under different 
names. In ancient Greece, Hippocrates described a distinct disease with mental and 
physical symptoms as melancholia, derived from “melas” (black) and “kholé” (bile). 
Compared to what we call depression nowadays, melancholia contained a wider array of 
symptoms: sadness, dejection, despondency, fear, anger, delusions and obsessions (1). 
In 1621, Robert Burton published the book “The anatomy of melancholy”, in which several 
underlying theories were described and treatment methods such as sufficient sleep and a 
healthy diet were suggested (2). In 1856, Louis Delasiauve, a French psychiatrist, first used 
the word depression to refer to psychiatric symptoms (3). From that time on, the term 
depression started to gain use in medical papers. The first Diagnostic and Statistical 
Manual of Mental Disorders (DSM-I) in 1952 contained the diagnosis ‘depressive reaction’, 
defined as an excessive reaction to internal conflict or an identifiable event. The term Major 
Depressive Disorder (MDD) was introduced in the seventy’s and incorporated in the DSM-
III in 1980 (4).  
Before the official introduction of what we now call antidepressants, other 
substances were used for a similar effect. In the eighteen hundreds, St. Johns Wort was 
used to relieve symptoms of depression. Around 1850, opium was approved as treatment 
for melancholia and in the 1930s amphetamines were introduced. Nowadays, St. Johns 
Wort is mostly known for its drug interactions, opioids are mostly prescribed for pain 
relieve and amphetamines are used in the treatment of attention deficit hyperactivity 
disorder (ADHD) and as a recreational drug. The discovery of the first ‘real’ antidepressant 
drug took place in 1951 when chemists had developed an antitubercular drug called 
isoniazid, later followed by iproniazid, which initiated side effects such as euphoria and 
increased appetite (5, 6). These effects were then successfully studied in a clinical trial 
with depressed patients by Loomer et al. and as a result iproniazid, classified as a 
monoamine oxidase inhibitor (MAOi), became the first official pharmacological treatment 
of depression. This discovery was quickly followed by a successor, also more or less 
invented by accident. Dr. Ronald Kuhn was examining imipramine for the treatment of 
schizophrenia. While it lacked antipsychotic properties, it turned out to have 
antidepressant abilities. Imipramine, a tricyclic antidepressant (TCA), with the name of this 
category based on the three benzene ring molecular core, was approved for treatment of 
MDD in 1959 (7). Meanwhile, researchers were studying underlying mechanisms of 
depression and attention was drawn to depleted concentrations of, among others, 
serotonin (8). Eli Lilly (a pharmaceutical company) began to develop drugs specifically 
aiming at this underlying mechanism. In 1975, Wong et al. published a first report on a 
selective serotonin reuptake inhibitor (SSRI), in this case fluoxetine. While fluoxetine was 
being tested, another SSRI, Zimelidine, was developed and first sold in Europe in 1982. 
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However, within a year and a half of its introduction, it was withdrawn from the market due 
to heavy side effects. In the successive years, fluvoxamine and fluoxetine entered the 
markets, later followed by the other SSRIs. 
After introduction of MAOi’s, TCAs and SSRIs, several other antidepressants have 
been developed and approved. In 1989 the FDA approved the use of bupropion (an 
aminoketone) for treatment of MDD (9). Venlafaxine, a serotonin norepinephrine reuptake 
inhibitor (SNRI), first came on the market in 1993 (7). The most recent antidepressant to 
have been approved (2013) is vortioxetine, a serotonin modulator and stimulator. Despite 
the variety of antidepressants available, not all patients respond to treatment with the 
currently available antidepressants. Therefore, research continues to focus on finding new 
drugs that target different receptors (10).  
Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine 
reuptake inhibitors (SNRIs): mechanisms of action 
The main focus of this thesis lies on two major antidepressant drug classes: selective 
serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors 
(SNRIs). There are currently six SSRIs marketed: citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine and sertraline. SNRIs currently registered as antidepressants are 
venlafaxine and duloxetine.  
Selective serotonin reuptake inhibitors (SSRIs) 
Serotonin has many important functions and can be found in the enteric nervous system, 
the central nervous system (CNS) and in blood platelets. Serotonin and serotonin receptors 
are important in the regulation of many brain functions and in critically important functions 
of many human organ systems outside the CNS (11). In the CNS, serotonin is mostly 
produced in neurons originating in the midline of the brainstem, where axons form a 
neurotransmitter system reaching most parts of the CNS. On a microlevel, serotonin is 
released into the synapse (a gap between two neurons) and recognized by receptors of 
the postsynaptic cell. When research discovered associations between low serotonin 
concentrations and depressive symptoms (12), the pharmaceutical industry started 
focusing on developing medicines specifically targeting those concentrations. SSRIs 
decrease the reuptake of serotonin in the serotonergic presynaptic terminals by inhibition 
of the serotonin transporter, leading to increased synaptic concentrations of serotonin. 
However, a definitive theory of how these changes lead to anti-depressive and anti-anxiety 
effects is unknown. 
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Serotonin norepinephrine reuptake inhibitors (SNRIs) 
SNRIs have the same mechanism of action as SSRIs except for the selectiveness for the 
serotonin receptor. SNRIs also inhibit the reuptake of the neurotransmitter norepinephrine, 
leading to an increase of both serotonin and norepinephrine in the synapse. Dual 
inhibition of serotonin and norepinephrine reuptake can offer advantages over other 
antidepressant drugs by treating a wider range of symptoms (13, 14).  
Current use in daily practice 
Although the name suggests otherwise, antidepressants are not only prescribed for 
depressive disorders. A recent study in Canada has looked at treatment indications for 
antidepressants in primary care between 2006 and 2015 (15). During the study period, 
101.759 prescriptions of antidepressants were written. Only 55.2% of the prescriptions 
was prescribed for depression; 18.5% was prescribed for anxiety disorders, 10.2% for 
insomnia, 6.1% for pain and 4.1% for panic disorders. Over time, the percentage of 
antidepressants prescribed for depressive disorders decreased significantly.  
Over the years, an incredible increase in the use of antidepressants is visible. In 
the Netherland, antidepressant use increases with approximately 1.5% each year, currently 
resulting in an estimated 6.5% of the population using antidepressants (16). In 2011-2014, 
12.7% of persons aged 12 and over in the United States reported antidepressant use in 
the last month compared to 7.7% in 1999-2002 (17). In the United Kingdom a rise was 
observed from 6.2% in 1995 to 13.0% in 2011 (18). The increase in antidepressant 
prescriptions was largely driven by a rise of SSRI prescriptions; TCA prescriptions 
remained relatively stable. Additionally, many patients continue to take medication for a 
longer period: over 60% of American continue medication for 2 years or more and 14% 
continues medication for 10 years or more (17). Women in their reproductive ages are 
three times as likely to use antidepressants compared to men (17).  
Use of antidepressants in the perinatal period 
In case of a pregnancy, decisions regarding the use of antidepressants are complex. When 
antidepressants were still new and rising, teratogenicity was largely unknown and clinical 
practice undocumented. As research has advanced, guidelines started to emerge. In part 
I of this thesis we focus on guidelines on management of antidepressants in the perinatal 
period and adherence to the Dutch guideline, accompanied by prescription patterns 
observed in a 16-year time period in the Netherlands. In part II we describe the set-up and 
first results of the Stop or Go trial, giving insight in the efficacy of antidepressants in the 
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Objective: Several countries have developed Clinical Practice Guidelines (CPGs) 
regarding treatment of perinatal depressive symptoms and perinatal use of antidepressant. 
We aimed to compare guidelines to guide clinicians in best clinical practice.  
Methods: An extensive search in guideline databases, MEDLINE and PsycINFO was 
performed. When no guidelines were (publicly) available online, we contacted psychiatric-
, obstetric-, perinatal- and mood disorder societies of all first world countries and the five 
largest second world countries. Only CPGs adhering to quality criteria of the AGREE 
instrument and including a systematic review of evidence were included. Data extraction 
focused on recommendations regarding continuation or withdrawal of antidepressants and 
preferred treatment in newly depressed patients.  
Results: Our initial search resulted in 1,094 articles. After first screening, 40 full-text 
articles were screened. Of these, 24 were excluded for not being an official CPG. In total 
sixteen CPGs were included originating from 12 countries. Eight guidelines were perinatal 
specific and eight were general guidelines.  
Conclusions: During pregnancy, four guidelines advise to continue antidepressants, while 
there is a lack of evidence supporting this recommendation. Five guidelines do not 
specifically advice or discourage continuation. For new episodes, guidelines agree on 
psychotherapy (especially cognitive behavioral therapy) as initial treatment for mild to 
moderate depression and antidepressants for severe depression, with a preference for 
sertraline. Paroxetine is not preferred treatment for new episodes but switching 
antidepressants for ongoing treatment is discouraged (three guidelines). If mothers use 
antidepressants, observation of the neonate is generally recommended and breastfeeding 
encouraged. 
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INTRODUCTION 
Depression is a common mental disorder and the leading cause of disability worldwide 
(1). In high-income countries, up to 15 % of people experience at least one major 
depressive episode in their life (2, 3). Women in the Western world are affected twice as 
often as men (4). Perinatal depression (considered here as depression arising in the 
period from conception to the end of the first postnatal year) affects up to 15 % of women; 
a recent meta-analysis showed a pooled prevalence of 11.9 % of all pregnancies, without 
significant differences between prevalence estimates for the prenatal and postnatal periods 
(5).  
Several management options are available for depressive disorders (6). Most 
patients, 65-80 %, will be treated by a general practitioner (7-12), who are instructed to 
use a stepped care management approach (13). Especially in mild to moderate 
depression, these approaches recommend psychotherapy as first line treatment, before 
starting antidepressants. However, in current practice around 70 % of cases are primarily 
treated with antidepressants (9, 14-16). Subsequently, many patients continue to take 
medication for a longer period; for example, over 60 % of Americans continue medication 
for 2 years or more and 14 % continues medication for 10 years or more (17). Women in 
their reproductive ages are three times as likely to use antidepressants compared to men 
(17). In case of a pregnancy, decisions regarding the use of antidepressants are complex. 
Although antidepressants are generally considered safe to use during 
pregnancy, this remains controversial (18). Antidepressant use has been associated with 
an increased risk for cardiovascular malformations (19), persistent pulmonary hypertension 
of the neonate (20), poor neonatal adaptation (21), preterm delivery, lower birth weight 
(22) and psychiatric disorders in offspring (23)
Untreated perinatal depression is not risk free either. Children of women who 
suffered from depression during pregnancy have an increased risk of premature delivery, 
low birth weight, gestational hypertension (24, 25) and perinatal death (26). Perinatal 
depression can also lead to behavioral, emotional, cognitive and motor problems in early 
childhood (27, 28). Postnatal depression may influence the mother-infant relationship, 
which can lead to poor infant development and outcomes (29, 30). Together, decisions 
regarding the prevention and treatment of perinatal depression (including the use of 
antidepressants) are complex.   
To facilitate this decision-making, several countries have developed ‘Clinical 
Practice Guidelines’ (CPGs), to guide clinicians in choosing the most efficacious and least 
harmful intervention. According to the Institute of Medicine, CPGs are based on a 
systematic review of evidence and include recommendations to optimize patient care (31). 
The objective of this study was to review the content of the internationally available 
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Identification of guidelines 
We initially performed an extensive search in databases for clinical practice guidelines 
using the terms ‘pregnancy’, ‘mood disorders’, ‘depression’ and/or ‘antidepressants’. 
The following databases were searched: National Guideline Clearinghouse (US AHRQ), 
National Institute for Health and Care Excellence (UK): Evidence services, Canadian 
Medical Association Infobase: Clinical Practice Guidelines (CPG), Guidelines, National 
Health and Medical Research Council (NHMRC) (Australia): Clinical Practice Guidelines 
and the Guidelines International Network (G-I-N). Secondly, we searched MEDLINE 
(accessed via PubMed) using a combination of free text terms (antidepressant, pregnancy, 
antenatal period, depression, prenatal period, mental health), limiting the results with a 
filter to retrieve guidelines only. Thirdly, we searched PsycINFO using a combination of 
title keywords (depression OR mental health OR mood disorder AND guideline), since 
PsycINFO does not have a search limit for guidelines and would otherwise retrieve too 
many hits. 
Consecutively, we identified all professional societies of obstetricians and 
gynecologists and all professional societies of psychiatrists for countries for which we did 
not yet retrieve a guideline. For feasibility reasons we limited our search to societies of 
first world countries and the largest second and third world countries. First world refers to 
‘so called developed, capitalist, industrial countries, roughly, a bloc of countries aligned 
with the United States after World War II, with more or less common political and economic 
interests’ (source: nationsonline.org). These include 25 countries: USA, Canada, Australia, 
New Zealand, Japan, Korea, UK, France, Germany, Belgium, the Netherlands, Spain, Italy, 
Portugal, Turkey, Greece, Luxembourg, Israel, Austria, Switzerland, Ireland, Sweden, 
Norway, Iceland and Denmark. In addition, we searched for guidelines in large second 
and third world countries including Brazil, China, India, Mexico and South-Africa. When 
no guidelines were (publicly) available online, we contacted perinatal and mood disorder 
societies and send two reminders to non-responders.  
Last, we sent out an email to the members of the Marcé society (an international 
society for perinatal health) and to our international contacts asking for information on 
missing guidelines, independent on country of origin.  
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NGC: National Guideline Clearinghouse; NICE: National Institute for Health and Care Excellence; CMA: 
Canadian Medical Association Infobase; NHMRC: National Health and Medical Research Council; G-I-N: 




Records screened (n=1,094) 
NGC  n=119 
NICE  n=656 
CMA  n=53 
NHMRC  n=4 
Guidelines n=110 
G-I-N  n=58 
Pubmed  n=22 
PsychINFO n=72 
Full-tekst articles assessed for 
eligibility (n=40) 
Guidelines included in review 
(n=16) 
Records excluded (n=1,062) 
- Lack of relevance (n=1,075) 
- Old version / rescinded (n=2) 
- Duplicates (n=2) 
- No access to abstract (n=1) 
Records included through 
professional institutions (n=4) 
Records included through Marcé 
Society and international contacts 
(n=4) 
Articles excluded (n=24) 
- Not an official CPG 
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Selection of guidelines 
Only CPGs, defined as statements that include recommendations, intended to optimize 
patient care, that are informed by a systematic review of evidence and an assessment of 
the benefits and harms of alternative care options, were selected. These should adhere to 
the quality criteria of the Appraisal of Guidelines for Research and Evaluation (AGREE) 
instrument (www.agreetrust.org). To avoid documents not meeting these quality criteria, 
consensus statements and guidance papers were excluded from this review. There were 
no limits for publication date or language. CPGs that did not comment on the perinatal 
management of mood disorders and/or on the perinatal use of antidepressants were 
excluded. Only the latest or more complete version of a guideline was selected when 
several versions of the same guideline were available. 
Data extraction 
Data extraction focused on recommendations before, during, and after pregnancy. 
Recommendations were investigated both for newly arising symptoms of depression and 
for pre-existent antidepressant use. We included recommendations regarding 
management of pre-existent antidepressant use, preferred treatment in newly depressed 
patients and breastfeeding with antidepressants. Recommendations were scored as 
follows: (blanc) no mention of the measure in the guideline, (0) measure mentioned in the 
guideline but without a clear direction of the recommendation (no positive or negative 
advice), (+) measure advised by guideline or (-) measure discouraged by guideline.  
RESULTS 
Our guideline database search strategy produced a set of 1,000 articles. Our Pubmed 
search added another 22 articles and our PsycINFO search 72. Of these 1,094 articles, 
1,062 were excluded after screening on title and abstract (Figure 1). Our search strategy 
through the professional societies, the Marcé Society and international contacts resulted 
in an additional eight articles. After thorough assessment, 24 articles were excluded for 
not being an official CPG. This resulted in a total of 16 guidelines originating from 12 
countries (6, 32-46). Additionally, we received information on the absence of a national 
guideline from the following countries: Austria, Belgium, France, Israel, Luxembourg, 
Mexico, Portugal, South-Africa, Sweden, Switzerland and Turkey. Guidelines from India 
and Israel are in progress. 
Table 1 shows the specifics and recommendations of these guidelines. Eight 
guidelines were exclusively on perinatal management; the remaining guidelines were 
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general guidelines on treatment of depression but included a section on perinatal 
recommendations.  
Pre-pregnancy 
Three guidelines discourage switching antidepressants. The Dutch Society of Obstetrics 
and Gynecology (NVOG; the Netherlands) advises to continue antidepressants if the 
patient is psychiatrically stable.  
With regard to initial therapy for new depressive symptomatology, the American 
Psychiatric Association (APA; USA), Centre of Perinatal Excellence (DOPE; Australia) and 
National Institute for Health and Care Excellence (NICE; UK) guideline give detailed 
recommendations. All three advise psychotherapy as initial treatment. In more severe cases 
of depression, the COPE and NICE guidelines advise antidepressants as initial therapy. 
Pregnancy 
During pregnancy, four guidelines advise to continue antidepressants. Five other 
guidelines mention the possibility of continuation but do not specifically advice or 
discourage continuation. Three guidelines discourage switching antidepressants during 
pregnancy. In contrast, the Danish guideline promotes switching when unfavorable 
antidepressants (paroxetine and fluoxetine) are used. 
Most guidelines agree on psychotherapy as initial treatment for mild to moderate 
depression and antidepressants as initial therapy for severe depression. Only the American 
College of Obstetricians and Gynecologists (ACOG; USA) guideline recommends 
antidepressants as preferred initial therapy instead of psychotherapy and independent of 
symptom severity. 
There is general consensus that potential harms and benefits of antidepressants 
during pregnancy should be discussed by the clinician with the patient. This way, patients 
can make well-informed decisions on preferred treatment.  
Management around delivery 
Most guidelines recommend a hospital delivery, which is standard in most countries. In 
the Netherlands and Canada, home births are still common; therefore, these guidelines 
explicitly mention a hospital delivery with additional observation as preferred option.  
Postpartum observation of the neonate is generally recommended but the length 
of observation is variable (ranging from 12 hours to 3 days). The BC guideline (Canada) 
recommends more intense monitoring of the neonate, including pulse oximetry for early 
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BC (Canada) and NVOG (Netherlands) specifically recommend continuation of 
antidepressants to prevent relapse of depressive symptoms. For new episodes, most 
guidelines agree on psychotherapy as initial treatment for mild to moderate depression 
and consideration of antidepressants as initial therapy for severe depression. Most 
guidelines agree on encouraging breastfeeding, independent of the kind of 
antidepressant medication the patient is taking. The Nordic Federation of Societies of 
Obstetrics and Gynecology (NFOG; Norway) advises switching medication when 
breastfeeding with unfavorable medication. Sertraline is named as favorable medication 
mainly due to its low level in breast milk and infants’ serum. 
Medication preference 
Recommended medication preferences are often not pregnancy stage specific. In general, 
guidelines agree on avoiding paroxetine during pregnancy, since use of paroxetine is 
associated with increased risk of congenital cardiovascular malformations in the newborn 
(19). In addition, the ACOG guideline (USA) recommends fetal examination by 
echocardiography if the fetus is exposed to paroxetine during early pregnancy. 
Five guidelines marked fluoxetine as ‘unfavorable’, due to its long half-life and 
its presence in breast milk. Remarkably, the NHS (Spanish ministry of health, social 
services and equality; Spain) mentions fluoxetine as preferred medication.  
There is general consensus on sertraline as preferred medication by the 
guidelines mentioning preferences for the postpartum period, mainly due to its favorable 
profile during lactation (47). Canmat (Canadian) and the Danish guideline also mention 
citalopram as preferred medication because of its minimized risk during lactation and 
available data on effectiveness during the postpartum period (48). 
DISCUSSION 
For new depressive episodes there is general consensus within guidelines for what is 
considered ‘best clinical practice’. Guidelines recommend, independent of pregnancy 
stage, to discuss all potential treatment options available and their potential harms and 
benefits during and after pregnancy. Most guidelines agree that psychotherapy, especially 
Cognitive Behavioral Therapy (CBT), should be considered as initial treatment for mild to 
moderate depression, both during pregnancy and the postpartum period. Psychotherapy, 
such as CBT or interpersonal therapy, has a robust treatment effect for depressive disorder 
during pregnancy (49) and research to other treatment options like bright light therapy is 
still ongoing (50). In more severe cases, antidepressants are preferred treatment options, 
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although, until this date, there are no controlled studies on the effects of psychotropic 
medication for antepartum mental disorders (49); the consequence of ethical constraints 
of conducting clinical trials with pregnant participants. Paroxetine is not a first-choice 
treatment option, considering its possible increased risk for congenital heart 
malformations. Preferred medications during the perinatal period include sertraline and 
citalopram. Breastfeeding is encouraged with sertraline as preferred medication. 
More complicated is the management of pre-pregnancy use of antidepressants 
and continuation during pregnancy. Unfortunately, evidence on the risks and benefits of 
tapering antidepressants during pregnancy is limited. One naturalistic study (n = 201) of 
women with long standing depression (mean duration of illness 15.4 years) showed a 
significant increased risk of relapse in pregnant women who discontinued their 
medication, compared to continuing medication (44 (68 %) vs. 21 (26 %)) (51), while 
another naturalistic study (n = 778) showed no clear difference in relapse rates of 
depression (16 % in total) between women continuing or discontinuing antidepressants 
(52). Randomized controlled trials are currently lacking with only one RCT in progress 
(53). Four guidelines advise continuation of antidepressants during pregnancy, which is 
remarkable given the scarce evidence. Unfortunately, none of the guidelines discusses 
treatment options for patients with current depressive symptomatology despite 
antidepressant use.  
Most guidelines acknowledge the importance of personalized medicine. For 
suitable decision-making, the following should be taken into consideration: psychiatric 
history and indication for antidepressant medication, current psychiatric symptoms, 
previous attempts of tapering medication, availability of alternative treatment options such 
as preventive psychotherapy and the presence of a social support network. Moreover, 
clinical algorithms need to be developed to improve decision-making. Currently, a pilot 
study is being executed to investigate if a patient decision aid (PDA) tool can reduce 
decision-making difficulty and lead to better treatment outcomes in pregnant women with 
antidepressant use (54).  
Overall, the guidelines have good quality (55), but most CPGs were not 
specifically developed for pregnant women and contained limited information on the 
measures of implementation and audit of the proposed measures. In our review, only eight 
guidelines were perinatal specific. Moreover, as pointed out by Santos et al. (55), 
guidelines do not disclose recommendations on emerging clinical questions and on new 
available evidence.   
For this review, we did not include Clinical Consensus Statements (CSSs) 
because they were not developed in accordance with clinical practice guidelines. CSS 
reflect the expert views of a panel of individuals who are well-versed on the topic of interest 




statements might give different recommendations than stated in the CPGs. For example, 
an Austrian CSS suggests tapering of antidepressants two weeks before the due date to 
reduce neonatal adaptation problems (56). None of the CPGs mention this option, 
possibly because of available evidence suggesting reduction of exposure to SSRI’s at the 
end of pregnancy has no significant effect on improving neonatal health (57). In clinical 
practice CSSs and other guiding documents are frequently used instead of the formal 
guidelines and might contain a higher level of detail.  
In summary, this overview of information might be helpful for the development 
of new CPGs. Clearly there is a need for up-to-date and perinatal specific CPGs and CSSs 
to help clinicians and patients in decision-making. It is challenging to develop these CPGs 
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Background and objectives: Prescription rates of antidepressants during pregnancy 
range from 2-3 % in The Netherlands to 6.2 % in the USA. Inconclusive evidence about 
harms and benefits of antidepressants during pregnancy leads to variation in advice given 
by gynecologists and midwives. The objective was to investigate familiarity with, and 
adherence to the Dutch multidisciplinary guideline on Selective Serotonin Reuptake 
Inhibitor (SSRI) use during pregnancy by gynecologists and midwives in the Netherlands. 
Methods: An online survey was developed and send to Dutch gynecologists and midwives. 
The survey consisted mainly of multiple-choice questions addressing guideline familiarity 
and current practice of the respondent. Also, caregiver characteristics associated with 
guideline adherence were investigated. 
Findings: A total of 178 gynecologists and 139 midwives responded. Overall familiarity 
with the Dutch guideline was 92.7 %. However, current practice and advice given to 
patients by caregivers differed substantially, both between gynecologists and midwives as 
well as within both professions. Overall guideline adherence was 13.9 %. Multivariable 
logistic regression showed that solely caregiver profession was associated with guideline 
adherence, with gynecologists having a higher adherence rate (OR 2.10, 95 % CI 1.02–
4.33) than midwives.   
Key conclusion: Although reported familiarity with the guideline is high, adherence to the 
guideline is low, possibly resulting in advice to patients that is inconsistent with guidelines 
and unwanted variation in current practice.  
Implications for practice: Further implementation of the recommendations as given in the 
guideline should be stimulated. Additional research is needed to examine how 
gynecologists and midwives can be facilitated to follow the recommendations of the 
clinical guideline on SSRI use during pregnancy. 
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INTRODUCTION 
Worldwide, prescription rates of Selective Serotonin Reuptake Inhibitors (SSRIs) during 
pregnancy vary from 3.7% in the UK (1) to 6.2 % in the USA (2). In the Netherlands, 
approximately 2 % to 3 % of all women each year take antidepressant medication during 
their pregnancy (3, 4).  
The use of antidepressants during pregnancy is still controversial. Studies on 
risks of short- and long-term effects report conflicting results. Some studies found 
increased risks for pregnancy-induced hypertension (5), cardiovascular malformations (6), 
persistent pulmonary hypertension of the neonate (PPHN) (7), poor neonatal adaptation 
(8), preterm delivery and lower birth weight (9), poor motor development (10) and autism 
spectrum disorders in the offspring (11). Several other studies failed to confirm these 
findings (12-14). An explanation for these conflicting results is that most of these results 
originate from retrospective observational studies with a lack to distinguish the effects of 
antidepressants from other shared risk factors, notably their indications depression and 
anxiety.  
On the other hand, leaving depression or anxiety disorders untreated may be 
hazardous to the (unborn) child as well. The preventive effect of SSRIs for relapse of 
depression during pregnancy is indistinct. Two observational studies compared relapse 
rates in women who discontinued their medication with women who continued their 
medication (15, 16). One showed a significant increased risk of relapse in women who 
discontinued their medication (68 % vs. 26 %), but the other study failed to find such a 
difference. If women suffer from depression or anxiety during pregnancy, this could lead 
to, among other things, preterm birth and low birth weight (17) and behavioral, emotional, 
cognitive and motor problems in early childhood (18, 19). Again, the observational 
character of these studies preclude definite answers as continuation or discontinuation are 
not likely to be randomly occurring. Therefore, to date it is still impossible to make 
definitive statements about the harm/benefit ratio of continuing or discontinuing 
antidepressants during pregnancy.  
In the Netherlands, maternity care is organized in a so-called primary, secondary 
and tertiary care model. The primary care, for obstetric low-risk women, is led by midwives 
and General Practitioners (GPs). Secondary care consists of obstetricians and clinical 
midwives in general hospitals, and tertiary care comprises obstetricians and clinical 
midwives in academic hospitals (20). Together with midwives, GPs and obstetricians, 
several other health care professionals, such as psychiatrists, psychologists, pediatricians 
and clinical pharmacologists, can be involved in the care during pregnancy and could be 
consulted on the use of antidepressants during pregnancy. In order to avoid conflicting 
advice to the patient, the Dutch Federation of Obstetrics and Gynecology (NVOG) has 
developed a multidisciplinary guideline in 2012 regarding the use of SSRIs during 
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pregnancy (21). This guideline gives, among others, the following advice: Pre-pregnancy 
continuation of SSRIs if women are stable on this medication and psychiatric indication is 
correct, a hospital delivery under supervision of a midwife or gynecologist, a postpartum 
hospital stay of at least 12 hours and continuation of SSRIs postpartum to prevent postnatal 
depression. It is stated that there is insufficient evidence on the possible benefit of 
discontinuing SSRIs during pregnancy, with or without non-pharmacological alternatives, 
compared to the possible risk of relapse of depression to advice pregnant women to 
discontinue medication.  
Given that gynecologists and midwives have an important role in informing 
pregnant women on use of antidepressant medication, the objective of this study was to 
investigate if gynecologists and midwives were familiar with the multidisciplinary guideline 
as published in 2012, and what their routine care is regarding pregnant women using 
SSRIs. In addition, we tested if caregiver characteristics, such as gender and age, were 
associated with guideline adherence. 
METHODS 
Study design and procedure 
For this cross-sectional study a short online survey for gynecologists and midwives was 
developed. The survey was developed after a review of the scientific literature to identify 
caregiver characteristics associated with guideline adherence in general (22-27). Before 
widely distributing the survey, we conducted a pilot (n = 56) and modified some textual 
ambiguities. 
The following sociodemographic and professional variables were identified: 
Age, sex, place of employment (conurbation versus rural), years of professional 
experience, self-reported annual number of pregnant patients treated by the caregiver and 
self-reported annual number of pregnant patients on antidepressants. If caretakers treated 
no pregnant patients, they were routed to the end of the survey and excluded from analysis. 
To study guideline adherence, caregivers were first asked if they were familiar with the 
guideline (no / yes). Subsequently they received questions addressing their current 
practice, based on recommendations from the guideline. Participants were asked to rate 
on a Likert scale with 4 categories (never / sometimes / most of the time / always) how 
often they would give certain advice possibilities, such as continuing or discontinuing 
antidepressants, to patients. Further, the need for multidisciplinary consultation (no / yes, 
but only if there is a serious case / yes, always), secondary care (no / yes, one consultation 
/ yes, during the whole pregnancy) and extra prenatal screening (no / yes (specification 
if yes)) and indicated hospital delivery (no / yes) and/or postpartum hospital stay (no / 
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duration <6 hours / duration of 6-12 hours / duration >12 hours) was questioned. Finally, 
caregivers were asked about their personal opinion on potential iatrogenic effects of 
antidepressants during pregnancy (no / yes) and their confidence in results from scientific 
research (no / yes). It took approximately five minutes to complete the survey.  
The Erasmus Medical Center, Utrecht University and University Medical Center 
Groningen are currently performing a randomized controlled trial, ‘Stop or Go’ (28), to 
investigate the effectiveness of preventive cognitive therapy with guided tapering of 
antidepressants during pregnancy for relapse of depression as compared to continuation 
of antidepressants during pregnancy. The current survey was conducted as part of that 
study. Ethical approval for the present study was received from the local ethics committee 
of Utrecht University. 
Study population 
The survey was sent by e-mail to all 1012 gynecologists and 421 gynecologists in training 
that were registered at the Dutch Federation of Obstetrics and Gynecology (NVOG), 
including gynecologists that are not currently active or do not work within the field of 
obstetrics. They received a reminder after two weeks. To reach the 3150 midwives in the 
Netherlands (as measured at January 2015 (29)) we placed a call on the website of the 
Royal Dutch Federation of Midwives (KNOV), and sent an invitation to all general e-mail 
addresses of midwifery practices as could be found on the internet and reached out 
through the network from the ‘Stop or Go’ study. It was not possible to send all midwives 
a personal invitation.  
By clicking on a link to the survey, caregivers implicitly consented to participate. 
The initial e-mail explained that all answers were processed anonymously.  
Statistical analysis 
Descriptive statistics were used to outline caregiver characteristics, familiarity with the 
guideline and current practice. Differences between gynecologists and midwives were 
tested using chi-square tests. 
Logistic regression was used for the evaluation of the univariable and 
multivariable associations of caregiver characteristics with guideline adherence. We 
developed two composite outcome variables based on the answers on the current practice 
questions representing guideline adherence.  
1) Overall guideline adherence. Overall adherence to the guideline was defined
as caregivers advising patients to continue antidepressants, both pre-pregnancy and 
during pregnancy, while not advising patients to discontinue medication; indicating a 
need for multidisciplinary consultation; indicating no need for secondary care or extra 
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prenatal examination; and indicating a need for hospital delivery and postpartum hospital 
stay with a minimum of 12 hours. 
2) Guideline adherence during pregnancy. Since consultation pre-pregnancy is 
not routine care for obstetricians and midwives, a second composite variable representing 
guideline adherence was developed, equal to the overall guideline adherence variable 
but excluding caregiver advice pre-pregnancy. 
Next to these two composite outcome variables we selected three additional 
dependent variables for multivariable logistic regression: 3) Familiarity with the guideline, 
4) caregiver advice to continue antidepressants during pregnancy (Likert scale 
dichotomized into never/sometimes and often/always), and 5) caregiver advice to 
discontinue antidepressants during pregnancy (yes / no). 
We selected the following independent variables: Gender, type of caregiver, 
place of employment, years of professional experience, self-reported annual number of 
pregnant patients on antidepressants treated by caregiver, familiarity with the guideline, 
caregiver’s opinion on potential harmfulness of antidepressants during pregnancy and 
caregiver’s confidence in results from scientific research. 
Univariable associations between our dependent variables and all the 
independent variables were computed. Variables with a p-value <0.10 were entered into 
a multivariable logistic regression model. Independent variables with a two-sided p-value 
< 0.05 in the multivariable model were defined as statistically significant. All associations 
were expressed as odds ratios (OR) with 95% confidence intervals (95%CI). 





A total of 178 gynecologists and 139 midwives fully completed the questionnaire. Baseline 
characteristics of both groups are shown in Table 1. Based on reports of Nivel, the 
Netherlands institute for health services research, we were able to compare age and 
gender in our sample with that of the total caregiver population (29, 30). Our sample of 
gynecologists was overrepresented by women (72.5 % in our sample vs. 55.8 % in the 
total caregiver population). The study sample of midwives matched on age and gender 
with the target population. Self-reported percentage of pregnant women with 
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Table 1. Baseline characteristics of health care professionals 
 Gynecologists (n=178) Midwives (n=139) 
Gender, female (%) 129 (72.5) 136 (97.8) 
Age in years, mean (SD) 43.9 (9.4) 37.9 (10.8) 
Place of employment (%)   
 Conurbation 78 (43.8) 56 (40.3) 
 Rural 100 (56.2) 83 (59.7) 
Years of professional experience, mean (SD) 14.5 (8.9) 13.2 (9.8) 
Self-reported number of pregnant women seen by 
individual caregiver, per year (SD) 
428.6 (284.3) 282.1 (169.2) 
Self-reported number of pregnant women with 
antidepressants seen by individual caregiver, per year 
(SD) 
50.2 (48.7) 29.8 (35.4) 






Table 2 shows the results on the current practice questions. Most caregivers were familiar 
with the guideline (overall 92.7 %; 97.8 % of gynecologists and 86.3 % of midwives, 
p<0.01). Caregivers reported to act differently on multidisciplinary consultation, indication 
for secondary care and extra prenatal screening, and advice on hospital delivery and/or 
postpartum hospital stay. These differences were seen both within the professions as well 
as between the professions. 14.5 % of the respondents considered antidepressant use as 
an indication for extra prenatal screening, mostly additional advanced ultrasound 
investigation (80.4 %). Most caregivers (80.3 % of the gynecologists and 84.2 % of the 
midwives) indicated to advice a postpartum hospital stay of at least 12 hours or of 6 to 12 
hours.  
40.4 % of gynecologists and 61.9 % of midwives (p<0.01) considered 
antidepressants potentially harmful during pregnancy. Just over half of the participants 
(55.6 % of gynecologists and 54.0 % of midwives) would trust results from scientific 
research to direct their actions with regard to prenatal antidepressant use. 
Table 3 shows the results from the multivariable logistic regression on guideline 
familiarity. Less familiarity with the guideline was not only associated with type of caregiver, 
but also with an increasing number of years of professional experience (OR 0.93, 95%CI 
0.88–0.99) and a lower confidence in results from scientific research (OR 3.71, 95%CI 
1.38–9.99). 
We also evaluated participants’ rating of advice possibilities to patients pre-
pregnancy and during pregnancy using antidepressants. Opinions of both gynecologists 
and midwives on continuing medication, lowering dose and consultation options vary 
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widely. Figure 1 shows most caregivers (76.6 % to 83.1 %) always give some form of 
advice to patients using antidepressants, both before and during pregnancy. The full data 
on participants rating of advice possibilities can be found in the data supplement.  
 
Guideline adherence 
Overall self-reported guideline adherence (including advice both pre-pregnancy and 
during pregnancy) was 13.9 % among all caregivers (18.0 % in gynecologists and 8.6 % 
in midwives, Table 2). Results of the univariable analysis showed associations with self-
reported annual number of pregnant patients on antidepressants seen by the individual 
caregiver, type of caregiver (gynecologist or midwife) and confidence in results of 
scientific research (Table 3). Only type of caregiver remained significantly associated in 
the multivariable model; gynecologists had 2.08 higher odds (95%CI 1.02–4.33) to act 
according to the guideline. 
Self-reported guideline adherence during pregnancy (excluding advice in the 
pre-pregnancy period) among all caregivers was 20.5 %. Univariable analysis showed 
associations with a higher self-reported annual number of pregnant patients on 
antidepressants seen by the individual caregiver and increasing years of professional 
experience. Both remained significant in multivariable analysis, with OR 1.01 (95%CI 1.00-
1.01) and 1.03 (95%CI 1.00-1.06) respectively. 
 
Caregiver’s advice to continue and discontinue antidepressants during pregnancy 
Of all caregivers, 75.7 % often advised to continue antidepressant medication during 
pregnancy (Appendix 1). Univariable analysis showed associations with self-reported 
annual number of pregnant patients on antidepressants seen by the individual caregiver, 
type of caregiver, caregiver’s opinion that antidepressant use during pregnancy is 
potentially harmful and unfamiliarity with the guideline (Table 3). Only type of caregiver 
remained statistically significant in the multivariable model. Midwives reported to less often 
advice to continue antidepressants during pregnancy (OR 5.48, 95%CI 2.95–10.21).  
None of the independent variables showed a significant association at 
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Figure 1. Distribution in advice frequency given by caregivers pre-pregnancy and during 
pregnancy 
 
A: No advice given pre-pregnancy by caregiver. B: No advice given during pregnancy by caregiver. C: Advice 





This cross-sectional study investigated if gynecologists and midwives report to be familiar 
with the Dutch multidisciplinary guideline on the use of SSRIs during pregnancy, to adhere 
to this guideline in current practice, and whether specific caregiver characteristics were 
associated with guideline adherence. Familiarity with the guideline was high (92.7 %), 
however self-reported guideline adherence was low (13.9 %). Differences were seen within 
the caregiver professions as well as between the professions. No other caregiver 
characteristics showed important associations with guideline adherence.  
Guideline familiarity was significantly less amongst midwives compared to 
gynecologists. Although the guideline is available for all caregivers involved during 
pregnancy, the guideline working group did not include midwives and the Royal Dutch 
Organization of Midwives (KNOV) did not accredit the guideline, possibly explaining this 
difference. Familiarity with the guideline does not directly imply extensive knowledge of 
p = 0.43p < 0.01





































the content. Our survey showed self-reported current practice often differed between 
caregivers.  
Advice on continuing or discontinuing antidepressants, both before and during 
pregnancy, differed substantially between caregivers. In practice this may result in 
conflicting advice from different caregivers, creating a potentially difficult situation for 
vulnerable women. The same variation in advice was reported previously in a survey 
amongst Dutch General Practitioners (GPs) (31). Pre-pregnancy advice patterns of GPs, in 
around 80 % of the cases the prescribers of the medication (32), are probably more 
relevant than those of gynecologists and midwives. Gynecologists only see a selected 
group for pre-pregnancy advice, for example couples with fertility problems. Experience 
of midwives with pre-pregnancy advice will be even smaller. Resulting advice patterns 
should therefore be interpreted with caution.  
 Caregiver’s advice can be based on the guideline, on their personal opinion or 
on a request from the patient. The current results show that 16.9 % to 23.4 % of caregivers 
do not always give advice to their patient with regard to antidepressive medication. This 
is remarkable since antidepressant use during pregnancy justifies attention and 
consideration of the caregiver, amongst others due to the potential risks of antidepressants 
on birth outcomes and the effect of untreated symptoms on the neonate. Patients should 
always be informed on potential harms and benefits of medication and make a decision 
in consultation with the caregiver.  
Opinion on harmfulness of antidepressants during pregnancy, with 49.8 % of 
respondents perceiving antidepressants as being potentially harmful, is very illustrative of 
current best evidence, which is still indistinct. This percentage is relatively low compared 
to previously reported opinions of GPs and pharmacists in the Netherlands in 2006; 96 
% of GPs and 65 % of pharmacists believed antidepressants are associated with an 
increased risk of birth defects (31). A study amongst physicians of multiple hospital 
specialties in Latin America showed similar outcomes as ours with 49.2% of respondents 
considering antidepressants potentially harmful (33).  
Although extra, non-standard prenatal screening is not advised, 14.5 % of the 
respondents considered antidepressant use as an indicator for extra prenatal screening, 
mostly additional advanced ultrasound investigation. Such methods are quite expensive, 
which in turn may results in unnecessary health care costs. Given the increase in 
antidepressant use during pregnancy, this may increase future health care costs. On the 
other hand, introduction of each pregnant patient in a multidisciplinary team, which is 
advised by the guideline, does often not take place. Multidisciplinary consultation of 
women can lead to more efficient prenatal care and uniform advice to patients, thereby 
possibly decreasing costs and increasing patient satisfaction. 
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Only 13.9 % of caregivers reported overall guideline adherence, which seems 
to be lower than rates in other adherence studies among various specialty areas (34), but 
in line with previous guideline adherence research amongst midwives (35, 36). We used 
multivariable regression to investigate possible independent determinants of guideline 
non-adherence. Characteristics were selected based on previous research, showing 
positive and negative associations with knowledge of and adherence to guidelines in 
various specialty areas (22-27). In our survey, professional-related characteristics and 
perceptions did not explain a significant part of variance in non-adherence. Other often 
reported barriers for guideline non-adherence, such as patient preference or 
professional’s personal experience (24, 34), could play a part but were not investigated 
in this survey.  
  
Limitations 
Despite the significant results, there were some limitations. First of all, due to our 
recruitment method, it was not possible to calculate valid response rates. It was not 
possible to send the invitation to obstetric gynecologists only (the Dutch Federation of 
Obstetrics and Gynecology responded they do not register subspecialisations) or invite all 
midwives personally through email. This makes generalizability of our results uncertain. 
The self-reported number of pregnant patients on antidepressants was high with 
a mean 11.3 %, as compared to the national 2-3 % as reported in previous research (3, 
4). This could be an overestimation, but it is plausible that our response group actually 
has more experience with pregnant women using antidepressants and is therefore not 
representative. For example, gynecologists who work at a specialized outpatient clinic for 
obstetric patients with psychiatric disease will attract more patients with antidepressants. 
One possible consequence is that this leads to an overestimation of familiarity with and 
adherence to the guideline. Another possibility is that, because of their more extensive 
experience, these caregivers more often deviate from the guideline. Guidelines are 
developed using the most recent evidence but have to be updated regularly because of 
fast developing new findings. Recommendations from guidelines can be outdated, which 





From this cross-sectional survey it can be concluded that guideline familiarity is high, but 
there are large differences among gynecologists and midwives in views on managing 
women using antidepressants before and during pregnancy. This seems to reflect the 
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current state of literature, which shows inconclusive results on benefits and harms of 
antidepressants during pregnancy. Unfortunately, this could lead to giving advice to 
patients that is not in line with evidence based clinical guidelines. Qualitative research 
could explore reasons for guideline non-adherence and stimulate further implementation 
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Purpose: Management of mental illness in the perinatal period with antidepressants is 
controversial, since evidence emerged on potential harmful effects to the unborn child. 
However, over time the dispensing of antidepressants in the perinatal period has 
increased. We examined perinatal dispensing patterns over time and the role of a recently 
issued guideline in this regard. 
 
Methods: We identified a 16-year cohort of 153,952 Dutch pregnancies with a delivery 
date between January 1999 and December 2014. Data included exposure to Selective 
Serotonin Reuptake Inhibitors (SSRIs) related to phases of pregnancy (preconception, 
pregnancy and delivery, post-delivery). The chi-square test for trends was used. With 
standard logistic regression we explored the influence of patient characteristics on 
continuation of SSRIs during pregnancy. 
 
Results: A persistent significant rise of dispensing rates at preconception, in pregnancy 
and childbed was observed, with the largest increase during pregnancy (from 0.8% in 
1999/2000 to 2.1% in 2013/2014, chi-square for trend=141.735, p<0.001). A 
substantial change of practice in terms of the SSRI used (less paroxetine) and the policy 
towards continuation into pregnancy (more continuation over time) was visible. 
Concomitant use of psycholeptics halved the probability of continuation of SSRI use during 
pregnancy (OR 0.50, 95%CI 0.43-0.55, p<0.01). 
 
Conclusions: Dispensing rates of SSRIs steadily increased last 16 years, especially during 
pregnancy, caused by an increase in the proportion of women continuing their medication 
during pregnancy. In view of the demonstrated impact of uncertainty regarding 
effectiveness and safety of SSRIs in pregnancy, future research should involve more 
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INTRODUCTION 
Management of mental illness in the perinatal period, defined as the entire period of 
pregnancy, the preconception period and the postnatal period (the first year after birth), 
remains an area of discussion. Approximately 25% of women experience any psychiatric 
disorder in this period (1, 2). Next to psychotherapy, administration of psychotropic 
medication is a common treatment option (3). Antidepressants are the most frequently 
prescribed psychotropic drugs during pregnancy (4), selective serotonin reuptake 
inhibitors (SSRIs) in particular (5). Over the years, an increase in prescriptions of 
antidepressants in the perinatal period has been observed (5-8). A large cohort from 
Tennessee (US) for example showed an increase of pregnancies with antidepressant use 
from 5.7% in 1999 to 13.4% in 2003 (5); in the United Kingdom an increase was seen 
from 3.5% in 2004 to 5.0% in 2010 (7). A more recent study in France, on the other 
hand, showed a slight decrease in the prevalence of prescriptions from 2% in 2005 to 
1.7% in 2014 (9). 
The use of antidepressants during pregnancy, however, has become 
controversial as evidence emerged on potential harmful effects to the unborn child (10). 
It has been associated with increased risks for cardiovascular malformations (especially 
paroxetine, RR=1.43; 95%CI, 1-08-1.88) (11), persistent pulmonary hypertension of the 
neonate (12), poor neonatal adaptation (13), preterm delivery, lower birth weight (14) and 
psychiatric disorders in the offspring (e.g. mood disorders, autism spectrum disorder and 
behavioral disorder including ADHD, HR=1.27; 95%CI 1.17-1.38) (15). A trade-off seems 
present, as untreated depression during pregnancy is not free of risk for the child either: 
multiple negative child outcomes have been reported such as premature delivery, low 
birth weight and perinatal mortality (16-18). In early childhood it can lead to behavioral, 
emotional, cognitive and motor problems (19, 20). Additionally, chronic postnatal 
depression influences the mother-infant relationship (21, 22).  
 As a result, the affected pregnant women and health care professionals face 
complex decisions regarding initiation, continuation or discontinuation of SSRIs in the 
perinatal period; the dilemma’s involved are recognized (23). Internationally, guidelines 
agree on a limited set of recommendations, such as the universal obligation to inform 
patients in due time about risks and benefits of all treatment options, and the use of 
psychotherapy as preferred treatment in mild to moderate depression (24). But on key 
aspects of the dilemma, they are unclear, i.e. the first choice of an antidepressant or the 
need for a switch (or not) in case of pre-existing antidepressant use. A recent Dutch 
national survey among obstetricians and midwives showed that the advice provided to 
women in these instances varied considerably (25).  
 Despite considerable scientific efforts to obtain evidence on the risks and 
benefits of antidepressant use in the perinatal period, the available evidence is 
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unequivocal. Published studies are often retrospective and register-based, in part 
inevitable due to the ethical demands of research in this context. As professionals show 
divergent views on the undecided issues, the question is relevant what actual practice at 
the population level is in terms of SSRI use, what variation in medication dispensing can 
be observed before, during and after pregnancy, and what change over time –if any- is 
visible. 
In this study we present population-based information on medication dispensing 
and dispensing patterns related to the pregnancy phases over 16 years (with delivery dates 
between January 1999 and December 2014) in the Netherlands. We examine whether 
medication dispensing rates increase in accordance with trends observed in other 
developed countries. In addition, we examine the effect (or not) of the introduction of the 
Dutch multidisciplinary guideline in 2012 on continuation of SSRI use during pregnancy 
(26). The guideline recommends continuing SSRIs (without switching) in the perinatal 
period if women are stable on this medication and psychiatric indication is correct. 
Furthermore, we will look at specific SSRIs used over the years. We expect a decline in 
paroxetine dispensing rates during pregnancy as evidence suggests increased risks of 
paroxetine use on child outcomes compared to other SSRIs, and as the Dutch guideline 
recommends switching from paroxetine to another SSRI in the preconception period when 
possible. Lastly, we will examine whether patient characteristics are associated with 
continuation or discontinuation of SSRIs during pregnancy expecting impact of higher 
socio-economic status and multiparity on continuation rate. During the study period no 
relevant change was present regarding the reimbursement scheme of dispensed 





For this population-based study, a cohort of 153,952 Dutch pregnancies was identified 
after probabilistic linkage between the Out-patient Pharmacy Database of the PHARMO 
Database Network and the Netherlands Perinatal Registry (PRN). The PHARMO Database 
Network is a dynamic cohort of participants that includes drug-dispensing records from 
community pharmacies of approximately 25% of the Dutch population, collected since 
1998 (27). The PRN is a national registry that contains validated and linked data from 
midwives, gynecologists, general practitioners and pediatricians on 95% of all 
pregnancies with a minimal gestational age of 16 weeks in the Netherlands. More 
information on these databases and the probabilistic linkage can be found in the appendix. 
All pregnancies with a delivery date between January 1999 (therefore including 
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preconception data from 1998 onwards) and December 2014 were included. To be able 
to define drug dispensing in the 12-month period before conception and 12 months after 
delivery, women needed to be registered in the community pharmacy database of the 
PHARMO Database Network for both of these 12-month periods. 
 
Drugs of interest 
The out-patient drug dispensing during the 12-month period before conception until 12 
months after pregnancy was extracted from the Out-patient Pharmacy Database. All the 
drugs are coded according to the Anatomical Therapeutic Chemical (ATC) classification 
system (28). SSRIs were defined as products with an ATC code starting with N06AB 
(further defined onto the fifth level) and included citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine and sertraline. The SSRI drug-dispensing data contained the 
following information per dispensing: timing of dispensing (before, during or after 
pregnancy, based on dispensing date), regimen and quantity dispensed. Pregnancy 
duration was based on ultrasound or last menstrual period, as recorded in the PRN. For 
all other drugs information was available on second level (the therapeutic subgroup with 
two digits), with timing only (before, during or after pregnancy). Note that inpatient drug 




Women were defined as a user of a SSRI during one of the three phases (12 months 
leading up to pregnancy, during pregnancy and 12 months after pregnancy) if a 
dispensing of at least 28 days for a given phase was registered. This definition excluded 
women discontinuing SSRI use in that particular phase. For trend analysis, data was divided 
into groups of two years (based on year of delivery) and the chi-square test for trends was 
used. Special attention was given to the before-after 2012 comparison, as in 2012 the 
SSRI guideline was introduced. 
Having available user information, subdivided into three phases related to 
pregnancy, we could define the following seven patterns: 1) women who used SSRIs 
before pregnancy only, 2) women who used SSRIs both before and during pregnancy, 3) 
women who used SSRIs before, during and after pregnancy, 4) women who used SSRIs 
during pregnancy only, 5) women who used SSRIs both during and after pregnancy, 6) 
women who used SSRIs after pregnancy only, and 7) women who used SSRIs before and 
after pregnancy, but not during (recidivist). Percentages of each group were calculated 
per two-year time period to analyze whether dispensing pattern changed, in particular 
related to the introduction of the guideline. 
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 To examine the association between general patient characteristics and 
discontinuation of SSRIs during pregnancy, only data of women using SSRIs in the year 
before pregnancy (women from the patterns 1, 2, 3 and 7) were used. Characteristics 
studied were year of delivery, parity, socio-economic status (determined on basis of data 
per zip code from the Central Bureau of Statistics (CBS), divided in low, middle and high), 
co-dispensing of psycholeptics (ATC codes starting with N05; including antipsychotics, 
anxiolytics, hypnotics and sedatives) and number of other co-medications (defined as the 
sum of all other pharmacy registered dispensed drugs, excluding SSRIs and psycholeptics) 
in the year before pregnancy. First, we determined univariable associations between the 
dependent variable and all the independent variables. Variables with a p-value <0.10 were 
entered into a multivariable logistic regression model. Independent variables with a two-
sided p-value <0.05 in the multivariable model were defined as statistically significant. All 
associations were expressed as adjusted odds ratios (OR) with the respective 95% 





A total of 153,952 pregnancies in the Netherlands with a delivery date between January 
1999 and December 2014 were identified. The mean maternal age at delivery was 31 
years (standard deviation (SD), 5) and socio-economic status was low in 28%, middle in 
34% and high in 38%. Of these 153,952 pregnancies, 7,284 of pregnancies (4.7%) used 
SSRIs in one or multiple phases (before, during and/or after pregnancy). Mean maternal 
age at delivery for these pregnancies was similar (31 years (SD, 5)), socio-economic status 
differed slightly (shift to lower SES), with SES low in 35%, middle in 33% and high in 32% 
(p < 0.01) (supplementary table 1). There were another 536 (0.35% of all) women that 
received a dispensing of less than 28 days in the year before pregnancy, 63 (0.04%) 
women during pregnancy and 260 (0.17%) women in the year after pregnancy. These 
cases are excluded for further analysis. 
 
Dispensing patterns over time 
Table 1 shows SSRI dispensing rates in the year before pregnancy, during pregnancy and 
in the year following pregnancy, comparing 2-year groups. Dispensing rate universally is 
highest in the year before pregnancy (e.g. 3.9% in 2013/2014) and lowest during 
pregnancy (e.g. 2.1% in 2013/2014). A significant rise over the years can be observed 
for all phases (before pregnancy, chi-square for trend=48.411, p<0.001; during 
pregnancy, chi-square for trend=141.735, p<0.001; after pregnancy, chi-square for 
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trend=10.540, p=0.001), with the largest increase during pregnancy (from 0.8% in 
1999/2000 to 2.1% in 2013/2014). The trend was not interrupted in 2012, when the 
guideline was introduced.  
 
Table 1. Number of deliveries in which the women received a dispensing for a SSRI in the year 
before pregnancy, during pregnancy or in the year following pregnancy, per 2-year group based 
on delivery date. 
SSRI dispensing during 
 Total number of 
deliveries 




The year following 
pregnancy (%) 
1999/2000 6,172 170 (2.8) 50 (0.8) 133 (2.2) 
2001/2002 11,625 386 (3.3) 118 (1.0) 292 (2.5) 
2003/2004 14,201 437 (3.1) 181 (1.3) 388 (2.7) 
2005/2006 20,684 639 (3.1) 276 (1.3) 521 (2.5) 
2007/2008 28.231 935 (3.3) 425 (1.5) 742 (2.6) 
2009/2010 28,220 987 (3.5) 462 (1.6) 764 (2.7) 
2011/2012 22,652 906 (4.0) 493 (2.2) 681 (3.0) 
2013/2014 22,167 856 (3.9) 461 (2.1) 677 (3.1) 
 
 
 Figure 1 shows starting and stopping scenarios of SSRI use, comparing 2-year 
groups. In the early years of our cohort, most women using SSRIs in the year before 
pregnancy (2.8% in 1999/2000) discontinued SSRIs during pregnancy (81% in 
1999/2000), while after 2012 only 54% discontinued medication (chi-square for 
trend=25.256, p<0.001), which is illustrated in figure 2. The percentage of women 
starting medication during pregnancy (without use in the year before pregnancy) does not 
alter much over the years (0.27% in 1999/2000 and 0.28% in 2013/2014). A small 
proportion (17.6%) of women who discontinued SSRIs during pregnancy, restarts SSRIs 
postpartum (recidivist, pattern 7), ranging from 19.0% in 2001/2002 to 14.9% in 
2013/2014. Finally, the percentage of women who initiated SSRIs in the first year 
following pregnancy, without use in the year before pregnancy or during pregnancy 
decreased from 1.08% in 1999/2000 to 0.91% in 2013/2014. No obvious change in 
trend is visible after introduction of the guideline in 2012. 
 Concomitant use of psycholeptic was highly prevalent: Of the 5316 women using 
SSRIs in the year before pregnancy, 44.6% also used psycholeptics in that year. A mean 
number of 4.0 (SD 2.7) other co-medications were used in the year before pregnancy by 
this group (supplementary table 1).  
Table 2 relates patient characteristics to the decision to continue SSRI use during 
pregnancy. All variables tested univariable were included in the multivariable model. In 
the multivariable model, a more recent delivery increased the odds of continuation with 
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10% per calendar year (OR 1.10, 95%CI 1.08-1.11, p<0.01); women with low SES were 
less likely to continue during pregnancy (OR 0.87, 95%CI 0.75-1.00); a higher parity 
increased the odds (with 15% per additional pregnancy) of continuation (OR 1.15, 95%CI 
1.09-1.21, p<0.01); concomitant use of psycholeptics however halved the probability of 
continuation of SSRI use during pregnancy (OR 0.50, 95%CI 0.43-0.55, p<0.01). The 
mean number of non-psycholeptic co-medications as such was not associated with 
continuation of SSRIs (OR 1.00, 95%CI 0.98-1.02, p=0.92).  
 
Figure 1. SSRIs perinatal dispensing rate per time period of interest per 100 pregnancies in the 
Netherlands, 1999-2014 
 
1 = the year before pregnancy, 2 = during pregnancy, 3 = the year after pregnancy. 
Complete data on all three phases was available for all women and thus the number of women at risk for each bar 
(1, 2 and 3) per 2 years are comparable. E.g. a woman with a delivery date in 199, who took SSRIs during all three 
phases (before, during, after) is represented in blue in all three bars (1, 2, 3) of the 1999 column. 
 
Individual drugs 
Of the six SSRIs dispensed, combining all years, paroxetine was the most frequently 
dispensed, accounting for 42.3% in the year before pregnancy, 41.3% during pregnancy 
and 46.0% in the year following pregnancy. However, a significant change in the selection 
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of paroxetine dispenses decreased steeply, as did the share of this particular SSRI among 
users. Especially citalopram and sertraline showed an increase, both absolute and relative, 
over time. During pregnancy, the same relative decline of paroxetine dispenses was 
observed, however without a concomitant absolute decrease as in general dispensing 
during pregnancy increased due to less discontinuation. In the year after pregnancy again 
both relative and absolute dispensing of paroxetine decreased again, although paroxetine 
still is the most often dispensed SSRI in 2013/2014. 
 Of the (all years combined) 1986 women who used SSRIs in the year before 
pregnancy and who continued medication during pregnancy, 127 women (6.4%) switched 
from SSRI at some point before, during or after pregnancy (supplementary table 2). No 
change in trend over the years was observed (chi-square for trend=5.577, p=0.590). 
 
Table 2. Univariable and multivariable associations between patient characteristics and continuing 
pre-conceptive SSRI use during pregnancy 
 Univariable outcome Multivariable outcome 
 cOR (95%CI) p-value aOR (95%CI) p-value 
Year of delivery 1.10 (1.08-1.12) < 0.01 1.10 (1.08-1.11) < 0.01 
Parity 1.15 (1.09-1.22) < 0.01 1.15 (1.09-1.21) < 0.01 
Socio-economic status     
 Low 0.86 (0.75-0.98) 0.03 0.87 (0.75-1.00) 0.05 
 High 0.99 (0.87-1.13) 0.88 0.97 (0.84-1.11) 0.64 
Concomitant use of psycholeptics 0.47 (0.42-0.53) < 0.01 0.50 (0.43-0.55) < 0.01 
Number of co-medications 0.98 (0.96-1.00) 0.03 1.00 (0.98-1.02) 0.92 
cOR = crude odds ratio, aOR = adjusted odds ratio, CI = confidence interval 
 
Figure 2. Percentage of women with SSRI dispensing in the year before pregnancy continuing 
during pregnancy in the Netherlands, 1999-2014 
 






























Figure 3. Relative and absolute dispensing rates per specific SSRI before, during and after 
pregnancy in the Netherlands, 1999-2014 
 
A. Relative SSRI dispensing in the year before pregnancy; B. Absolute SSRI dispensing in the year before pregnancy; 
C. Relative SSRI dispensing during pregnancy; D. Absolute SSRI dispensing during pregnancy; E. Relative SSRI 
dispensing in the year after pregnancy; F. Absolute SSRI dispensing in the year after pregnancy. Each year 
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DISCUSSION 
This large 16-year population-based study shows a general trend of increased SSRI use in 
the year before pregnancy, during pregnancy and in the year following pregnancy, a 
substantial change of practice with regard to continuation over time (more continuation), 
initiated already before introduction of the 2012 guideline, and a changed pattern in terms 
of particular SSRI used. An increased preference for both citalopram and sertraline, at the 
expense of paroxetine. The latter change is a change in practice, rather than in individual 
patients, as switching between specific SSRIs is rare (6.4%). Higher parity and more recent 
delivery increased the odds of continuation, while low SES and concomitant use of 
psycholeptics substantially decreased the continuation rate. 
To our knowledge, this study is the largest to examine trends in SSRI use related 
to pregnancy in the Netherlands, irrespective of drug choice. Two Dutch author groups 
previously reported on more selected samples. Ververs described the experience of a 
cohort of 29,005 deliveries between January 2000 and July 2003, which was made 
available from one health care insurance company (29). Here 2.2% of women used SSRIs 
before pregnancy, with a decrease to 1.4% in the third trimester and an increase to 2.3% 
in the post-delivery period. Bakker et al reported on a cohort of 14,902 pregnancies with 
deliveries between 1995 and 2004 available from the Interaction Database (IADB.nl) (6). 
Over these years, the exposure rate to SSRIs in the year preceding delivery increased from 
1.2% to 2.9%. The data on the early years of our cohort fits to these observations and show 
that the growing trend has persisted 10 years beyond 2004. Research among the general 
Dutch population within the age category of 25 to 49 years (thereby including our target 
population) also reported an increase in SSRI use from around 2.5% in 1998 to 4.0% in 
2004. After 2004 a mild decrease was seen to around 3.7% in 2010 (30). Our data did 
not show such a decrease, possibly because of our specific target population, but 
nonetheless rates in the year before pregnancy are a good match. A more recent cohort 
study examined SSRI prescription in several European countries over the years 2004 to 
2010. Prescription rates before, during and after pregnancy in our study were comparable 
to Denmark (4.1%, 2.3% and 4.1% respectively) and Italy (4.4%, 1.6% and 2.4% 
respectively), but prescription rates in the UK were considerably higher with 8.8 to 9.6% 
of women using SSRIs in the year before pregnancy (7). Compared to the USA, where 
SSRI prescription rates during pregnancy increased from 5.7% to 13.4% in 2003, 
prescription rates in European countries are low (5).  
 A trend towards more continuation is observed over the years, without an obvious 
change in trend after introduction of the 2012 guideline, which recommends continuation 
of SSRIs if women are stable on this medication and psychiatric indication is correct (26). 
This recommendation is a result of insufficient evidence on benefits of SSRI discontinuation 
during pregnancy, with or without non-pharmacological alternatives, and inconclusive 
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evidence on the risk of relapse of depression when SSRIs are discontinued. A hypothesis 
is that the relatively low percentage of women receiving a SSRI in general compared to 
other countries such as the USA, indicates a more personalized drug treatment for severe 
psychiatric disorders in low prescription countries, therefore warranting continuation of 
SSRI during pregnancy to prevent relapse of severe psychiatric disorder. Interestingly, 
concomitant use of psycholeptics, associated with more severe psychiatric diagnosis, 
halved the probability of continuation of SSRI use during pregnancy. An explanation could 
be that women might think using multiple forms of psychotropic medication is harmful 
(cumulative effect); by self-tapering such women may think this benefits child outcome. 
Final interpretation of this interaction pattern requires more data e.g. on the severity of 
underlying disease. A higher parity was associated with increased odds on continuing 
medication. This could be explained by the high correlation of parity with age. A higher 
parity could indicate a longer duration of psychiatric disease and/or longer duration of 
antidepressant treatment; this in turn might lead to an increased perceived dependence 
on antidepressant treatment (31). Another explanation could be that multiparous women 
with previous healthy infant(s) while using antidepressants, are more likely to be willing to 
continue a consecutive pregnancy on SSRIs due to the assigned benefits.  
 There has been a major shift in specific SSRIs dispensed over the years. Where 
paroxetine was responsible for 58.5% of all SSRIs dispensed in 1999/2000, it only 
accounted for 27.6% of the SSRIs dispensed in 2013/2014. This seems to be an 
appropriate reaction to the increasing amount of evidence showing a higher rate of 
negative consequences on birth outcomes in paroxetine use compared to the other SSRIs 
(32-38). Overall, paroxetine remained the most frequently dispensed SSRI, while a 
population-based study from Denmark, Iceland, Norway and Sweden showed paroxetine 
was the least prescribed SSRI in the period of 2008 to 2012 (39). 
Insufficient evidence on the risk of relapse of depression when discontinuing 
medication during pregnancy is available. The first randomized controlled trial is being 
executed at the moment (40), but so far only two naturalistic studies report on relapse 
rates in women continuing or discontinuing antidepressants during pregnancy (41, 42). 
Where the first study reported a significant increased risk of relapse in women who 
discontinued their medication compared to women continuing medication (86% vs. 26%), 
the second study failed to find such a difference. In our current study, only a small 
proportion of women restarted medication after discontinuation during pregnancy, which 
may reflect the relapse rate of the psychiatric disorder. The possibility of a short 
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Strengths and limitations 
The size and composition of the Out-patient Pharmacy Database is a major strength of this 
study. It includes representative data on approximately 25% of the Dutch population, 
thereby allowing for fairly good estimates on the level of the Dutch population. Data was 
available from a year before conception until the end of the year following pregnancy. An 
accurate conception date could be obtained from the PRN database based on ultrasound 
or the last menstrual period and the exact delivery date was also present in the PRN 
database. However, even this dataset had its limitations. Exact timing of drug dispensing 
for this study was defined according to before, during and after pregnancy, enabling us 
to rule out the possibility that drugs dispensed just before pregnancy were still being used 
in the first trimester of pregnancy and so on. For some drug dispensing an unknown ATC 
code was registered, thereby potentially missing a small amount of SSRI dispensing 
leading to underreporting of SSRI dispensing among the target population.  
A limitation of prescription registry data is that actual use may be less (non-compliance), 
or more (external sources of medication, shelf medication). Non-compliance is the most 
likely weakness, due to an increasing societal and professional reluctance to 
take/prescribe drugs during pregnancy, and psychotropic drugs in particular (43). In this 
study we assume the likelihood of underestimation to be very small. Last, information on 
pregnancies that ended before a gestational age of 16 weeks was excluded in our study 
as the PRN database only contains information of pregnancies of >= 16 weeks of gestation. 
However, SSRIs do not seem to increase risk of miscarriage (44) and in addition patterns 




For more than a decade SSRI use before, during and after pregnancy shows a steady 
increase. Rise is most prominent during pregnancy, by the combined effect of a general 
rise in SSRIs use, and a change towards continuation rather than quitting SSRI use if women 
get pregnant. Despite a substantial shift in drug preference, paroxetine is still most 
commonly used. In view of the demonstrated impact of uncertainty regarding effectiveness 
and safety of SSRIs in pregnancy, future research should involve more detailed outcome 
research of SSRIs as it is, and research into viable alternatives (drug, non-drug) for the use 
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The PHARMO Database Network is a dynamic cohort of participants that includes, among 
other information, drug-dispensing records from community pharmacies for more than 
three million individuals in the Netherlands (approximately 25% of the Dutch population) 
collected since 1998 [1]. The PRN is a national registry that contains validated and linked 
data from four independent databases: the national obstetric database for midwives (LVR-
1), the national obstetric database for gynaecologists (LVR-2), the national obstetric 
database for general practitioners (LVR-h) and the national neonatal/paediatric database 
(LNR) [2]. The registry contains information about care before, during and after delivery 
as well as maternal and neonatal characteristics (determinants) and outcomes of 95% of 
175.000 pregnancies annually in the Netherlands, with a minimal gestational age of 16 
weeks. The linkage method used here has been described elsewhere; it is generally based 
on the birth dates of the mother and the child and their approximate address (postal zip 
codes; covers 2000-5000 persons, 20-50 deliveries annually) [3]. The probabilistic 
record linkage here used techniques validated before with these datasets. Due to the 
favourable data characteristics in this case, accuracy is close to perfect [4, 5]. 
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Supplementary table 1. Characteristics of all women with SSRI use (n=7,284) before, during 
and/or after pregnancy and of women with SSRI use (n=5,316) in the year before pregnancy. 
 Full sample Women with SSRI use before pregnancy 
Age in years, mean (SD) 31.5 (4.7) 31.5 (4.8) 
Socio-economic status   
 Low 2451 (33.6) 1713 (32.2) 
 Middle 2420 (33.2) 1816 (34.2) 
 High 2371 (32.6) 1759 (33.1) 
Concomitant use of psycholeptics, yes (%) 2729 (37.5) 2369 (44.6) 
Number of co-medications, mean (SD) 4.0 (2.7) 4.0 (2.7) 
 
 
Supplementary table 2. Specific SSRIs used before and after switch in women using SSRIs in 
the year before pregnancy and continuing SSRIs during pregnancy and switching at some point 
before or during pregnancy. 
 SSRI use before switch, n (%) SSRI used after switch, n (%) 
Citalopram 30 (22.2) 34 (21.1) 
Escitalopram 10 (7.4) 9 (5.6) 
Fluoxetine 11 (8.1) 27 (16.8) 
Fluvoxamine 5 (3.7) 12 (7.5) 
Paroxetine 31 (23.0) 41 (25.5) 
Sertraline 48 (35.6) 38 (23.6) 
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Introduction: Approximately 6.2% of women in the USA and 3.7% of women in the UK, 
use Selective Serotonin Reuptake Inhibitors (SSRIs) during their pregnancies because of 
depression and/or anxiety. In the Netherlands, this prevalence is around 2%. 
Nonetheless, SSRI use during pregnancy is still controversial. On the one hand SSRIs may 
be toxic to the intrauterine developing child, while on the other hand relapse or recurrence 
of depression during pregnancy poses risks for both mother and child. Among patients 
and professionals there is an urgent need for evidence from randomized studies to make 
rational decisions regarding continuation or tapering of SSRIs during pregnancy. At 
present, no such studies exist.  
 
Methods / Design: ‘Stop or Go’ is a pragmatic multicenter randomized non-inferiority 
trial among 200 pregnant women with a gestational age of less than 16 weeks who use 
SSRIs without clinically relevant depressive symptoms. Women allocated to the intervention 
group will receive preventive cognitive therapy with gradual, guided discontinuation of 
SSRIs under medical management (STOP). Women in the control group will continue the 
use of SSRIs (GO). Primary outcome will be the (cumulative) incidence of relapse or 
recurrence of maternal depressive disorder (as assessed by the Structured Clinical 
Interview for DSM disorders) during pregnancy and up to three months postpartum. 
Secondary outcomes will be child outcome (neonatal outcomes and psychomotor and 
behavioural outcomes up to 24 months postpartum), and health-care costs. Total study 
duration for participants will be therefore be 30 months. We specified a non-inferiority 
margin of 15% difference in relapse risk.  
 
Discussion: This study is the first to investigate the effect of guided tapering of SSRIs with 
preventive cognitive therapy from early pregnancy onwards as compared to continuation 
of SSRIs during pregnancy. We will study the effects on both mother and child with a 
pragmatic approach. Additionally, the study examines cost effectiveness. If non-inferiority 
of preventive cognitive therapy with guided tapering of SSRIs compared to intended 
continuation of SSRIs is demonstrated for the primary outcome, this may be the preferential 
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INTRODUCTION 
Depressive disorder and anxiety disorders are the primary indications for the use of 
Selective Serotonin Reuptake Inhibitors (SSRIs). Worldwide, the SSRI prescription rate 
during pregnancy ranges from 6.2% in the USA (1), to 3.7% in the UK (2). The actual Dutch 
nationwide estimated use of SSRIs during pregnancy is about two percent (3, 4); while in 
the Rotterdam area this number is even as high as five percent (5). Nonetheless, SSRI use 
during pregnancy is still controversial. On the one hand SSRIs may be toxic to the 
intrauterine developing child, while on the other hand, relapse of depression and/or 
anxiety during pregnancy poses risks for both mother and child (6).  
The preventive effect of SSRIs for relapse of depression during pregnancy seems 
equivocal. One naturalistic study showed a significant increased risk of relapse in pregnant 
women who discontinued their medication compared to continuing medication (68% vs. 
26%), while another naturalistic study showed no clear difference relapse rates of 
depression (16% in total) between pregnant women continuing or discontinuing 
antidepressants (7, 8).  
Pregnancy-related complications both exist for women using SSRIs during 
pregnancy and women with untreated depression/anxiety during pregnancy, posing a 
dilemma for the treating physician who considers SSRI withdrawal. For example, studies 
found significantly increased risks for preeclampsia among women who use SSRIs and 
increased risks for pregnancy-induced hypertension in women with depression/anxiety 
during pregnancy compared to healthy controls (9, 10). 
Whether or not SSRIs are of direct influence on the newborn, both short- and 
long-term, is another unresolved issue. For example, a recent meta-analysis showed an 
increased risk for cardiovascular malformations (RR = 1.36) and septal heart defects (RR = 
1.40) with use of SSRIs (11). These findings were however not supported by a recent 
Nordic cohort study, which – after a sibling-controlled analysis – found no substantial 
increase in prevalence of overall cardiac birth defects for any SSRI (OR = 0.92) (12). 
Another example of evidence of a potential direct toxic effect is the association of SSRI 
use with persistent pulmonary hypertension (PPHN) of the neonate. A large cohort study 
from the Scandinavian national health registers showed a twofold-increased risk of PPHN 
with exposure later than gestational week 20 (OR = 2.1) (13). However, this risk appeared 
more modest (OR = 1.51) in a large cohort study from 46 US states (14). 
 Several other effects of SSRIs during pregnancy have been described, such as 
a higher risk of poor neonatal adaptation (OR = 5.07), respiratory distress (OR = 2.20), 
tremors (OR = 7.89), preterm delivery and small for gestational age, lower birth weight 
and lower Apgar scores at 1 and 5 minutes after birth (15, 16). Long-term effects on 
children are less often investigated. One systematic review found an adverse effect on 
children’s motor development but not on emotional or behavioral development (17). Two 
Chapter 6 
 94 
large studies reported on the association between maternal SSRI use and childhood autism 
spectrum disorders, but found conflicting results (18, 19). 
On the other hand, leaving depression or anxiety disorders untreated may be 
hazardous to the unborn child as well. At present, it is well known that children of women 
who suffered from anxiety or depression during pregnancy have an increased risk of 
adverse perinatal health outcomes, and behavioral, emotional, cognitive, and motor 
problems in early childhood (20, 21). It is also shown that the infant cortisol stress response 
is altered if the mother suffered from depression during pregnancy (22). One meta-
analysis showed an association of depression during pregnancy with preterm birth and 
low birth weight (23). Another more recent meta-analysis showed that depression during 
pregnancy is associated with premature delivery, but did not find associations with birth 
weight, neonatal intensive care unit admissions, preeclampsia, gestational age or Apgar 
scores (24). 
Overall, in clinical practice and literature, pregnant women express a strong 
preference for non-pharmacologic treatment of depression over antidepressant medication 
(25). Hence, cognitive behavioral therapy (CBT) could be a good alternative for SSRI use 
during pregnancy. According to a recent meta-analysis there is strong evidence that CBT 
interventions are effective for preventing depressive relapse during the perinatal period 
(26). A recent follow-up study showed that preventive cognitive therapy (PCT) has long-
term effects in preventing depressive relapse in patients with recurrent depression for over 
5.5-10 years after the sessions ended (27, 28). This preventive psychological strategy 
therefore seems promising in preventing depressive relapse, presumably also during 
pregnancy. Moreover, a recent study in the UK among non-pregnant patients showed that 
tapering antidepressants with therapy was as effective as continuation of antidepressants 
(Hazard Ratio 0.89) (29). Nevertheless, further investigation is necessary to assess 
effectiveness of tapering antidepressants with added PCT during the perinatal period.  
In conclusion, pregnant women and their clinicians face a dilemma, which is 
widely experienced in current practice (30). At present, there are no suitable data available 
to guide evidence-based decisions on SSRI continuation or discontinuation during 
pregnancy (31). Both the National Institute for Health and Clinical Excellence in the United 
Kingdom (NICE) guideline (32), and American Psychiatric Association (APA) (33) 
therefore recommend to discuss both possibilities with women. The recently developed 
Dutch multidisciplinary guideline advises to continue SSRI use during pregnancy, and 
furthermore advises a hospital delivery and neonatal observation based on the increased 
risk and the severity of the (rare) condition of PPHN and prevalence (25-30%) of children 
with neonatal abstinence after maternal SSRI use (34). Nonetheless, the need of 
randomized trials was stressed. Indeed, existing studies are observational and therefore 
their results do not fully allow causal inference nor definite conclusions for practice. 
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Trial objectives  
In this randomized controlled trial (RCT), the effect of preventive cognitive therapy (PCT) 
with guided tapering of SSRIs in early pregnancy will be compared to continuation of SSRIs 
during pregnancy. We will study effects on both mother and child with a pragmatic 
approach. The expectation is that tapering of SSRIs with added PCT does not increase the 
risk of clinically relevant maternal relapse or recurrence of depression or onset of anxiety 
disorders during pregnancy up to three months postpartum in excess of [absolute] 15% 
compared to continuation of SSRIs. If so, discontinuation is deemed non-inferior with 
regard to relapse/recurrence risk. Furthermore, we expect that tapering of SSRIs is better 
than continuation of SSRIs with respect to child development. Finally, but not 
unimportantly, we hypothesize that discontinuation will decrease total costs per woman 
and child on a 3 months and projected long term base, assuming no relevant effects of 
discontinuation on the mother and no effects on the child are found.  
 
 
METHODS / DESIGN 
Design & Setting 
The Stop or Go study is a pragmatic multi-center randomized controlled non-inferiority trial 
(RCT) in obstetric care. Women will be recruited during their first prenatal visit in 
midwifery practices (first echelon care) and hospitals (second and third echelons care), or 
through advertisement in (social) media. After inclusion, women will be randomly allocated 
into two groups: STOP or GO. Both groups will receive regular assessments throughout 
their pregnancy and up to 3 months post-partum. Permission will be asked to contact the 
Centre of Childhood (CJG) at 24 months after delivery for information on the development 
of the child. Total duration of the study for participants will therefore be 30 months. In 
Figure 1 an overview of the study design and main procedures is shown. 
 
Participants 
Women who are less than 16 weeks pregnant and use a SSRI primarily for depressive 
disorder, and are currently at least in remission or recovered (35), are invited to participate 
in the trial. Exclusion criteria are multiple pregnancy, as these women have a markedly 
increased obstetric risk, thereby threatening the homogeneity of the study population and 
thus potentially complicate the statistical analysis, and insufficient proficiency in Dutch or 
English, since our intervention is not yet available in other languages. Also, women will 
be excluded with severe medical conditions, such as oncology-related conditions or 
conditions that need urgent medical interventions, which involve treatment decisions 
overriding research participation. Exclusion criteria related to mental health are: current 
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mania or hypomania or a history of bipolar illness, suicidality and serious self-harm, any 
psychotic disorder (current and previous), current alcohol or drug misuse, predominant 
anxiety disorders and personality disorders that require psychotherapeutic treatment for 
more than 2 sessions a month. 
 
Assessment of eligibility 
After informed consent is obtained, a pre-assessment interview will be conducted, with the 
Structured Clinical Interview for DSM-disorders (SCID) (36) and the Hamilton Depression 
Rating Scale (HDRS) (37) to assess major DSM-IV Axis I psychiatric diagnoses and actual 
remission status and depressive symptoms respectively. Before randomization, study 
researchers will contact the medical professional who prescribed the SSRI medication to 
inform the professional about the study and discuss exclusion criteria as described above 
for study participation.  
 
Randomization 
Two hundred women will be randomized in a 1:1 allocation ratio to either the intervention 
arm (STOP) or the care as usual arm (GO). Randomization will be done with a web based 
computer-generated randomization schedule (a validated TENALEA Clinical Trial Data 
Management System; http://www.formsvision.com/) using permuted blocks of random 
size with a maximum of 16 and stratified for the number of previous depressive episodes 
(dichotomized). Based on a recent review (35), the participants are divided into groups 
of participants with 3 or less previous depressive episodes, versus 4 or more. Allocation 
of participants is concealed for study researchers.  
 
Interventions 
1. Tapering SSRI 
Women assigned to discontinuation of SSRIs will be referred to a psychiatrist trained in 
guiding tapering of SSRIs during pregnancy. They will plan and carry out SSRI 
discontinuation using an expert-based discontinuation protocol (38). The aim is to taper 
the use of SSRIs within four weeks, depending on patient preferences and on drug 
characteristics (e.g. half-life in the body). There are no restrictions on the use of medication 
like sleeping pills, paracetamol, and mild tranquillizers. All co-medication will be 
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Recruitment through midwifery practices (first echelon care) and hospitals (second and 
third echelons care), and approaching the general population using (social) media 
Screening: SSRI use and pregnancy duration 
Pre-assessment (T0): SCID and HRDS telephone interview, baseline questionnaires (T1) 
- Assessment at 24 and 36 weeks of pregnancy (T2, T3), delivery (T4), and 4 and 12 
weeks after delivery (T5, T6) 
- See Table 1 for an overview of the assessments. Assessments include questions on 
anxiety symptoms, depressive symptoms, childhood trauma, affect, dysfunctional attitudes, 
medication beliefs, medication adherence, quality of life, and health costs 
- Both groups receive obstetric care as usual 
Exclusion: 
- No SSRI use 
- More than 16 weeks pregnant 
- Declines to participate 
STOP-group: Guided tapering of 
SSRI according to protocol with 
preventive cognitive therapy 
GO-group: Continuation of SSRI 
(treatment as usual) 
Monitoring possible withdrawal 
symptoms 
Randomization (1:1) by a web-based computer-generated randomization program 
Exclusion: 
- Current depression as defined by 
HRDS (score >13) and/or SCID 
- No MDD in history 
- Severe comorbid psychiatric 
disorder 




2. Preventive Cognitive Therapy 
Trained psychologists will provide preventive cognitive therapy in the discontinuation arm. 
This psychological intervention has proven to be effective in relapse prevention (27, 39-
42). The current manual was evaluated in previous studies (27, 38, 41, 43).  
The intervention will be applied through VSee (www.vsee.nl), a HIPAA-compliant 
telehealth app.  Several studies demonstrated that psychological intervention as applied 
by telephone support is effective and there is some evidence that it might be effective to 
decrease postpartum depressive symptomatology (44-47). Although not tested during 
pregnancy, there are indications that antenatal telephone or online therapy is effective and 
convenient (48). 
The preventive psychological intervention consists of a minimum of eight weekly 
VSee sessions. These sessions are led by professional psychologists trained in cognitive 
behavioral therapy and may occur at any time of the day. The focus of the sessions is on 
identifying and teaching the participants to challenge dysfunctional beliefs, enhance recall 
of positive feelings and cognitions and a personal prevention plan is developed in which 
it is specified how the participant can prevent a depressive episode in the future. For each 
session the participant will receive some assignments of approximately 10 minutes per 
day. Treatment adherence will be monitored.  
 
3. Care as usual 
Women assigned to continuation of SSRIs (GO) obtain usual care. They will be instructed 
to consult their doctor as they regularly do, in line with the pragmatic nature of the study. 




Primary outcome of this trial is (cumulative) incidence of relapse or recurrence of a 
depressive episode (as defined by the SCID-I (36)) during pregnancy and up to 12 weeks 
postpartum. The SCID-I is assessed at baseline (T0) and 12 weeks postpartum (T6). If – 
based on assessment with the HDRS at fixed time-points – relapse/recurrence is 
suspected, the SCID-I will be performed intermittently. 
For registration of severity of depressive symptoms, the HDRS will telephonically 
be assessed additionally, at baseline (T0), at 36 weeks of gestation (T3), and 12 weeks 
postpartum (T6), and also intermittently, if necessary (37). When the HDRS at any stage 
turn out above cut-off scores, the participant will be called one week after initial 
measurement. The HDRS will be repeated to confirm or reject elevated scores. An adjusted 
telephonic version of the everyday problem checklist (EPCL) and pregnancy related life 
events will be assessed during each telephonic measurement (T0, T2, T3, T5 and T6).  
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Women will be asked to fill in questionnaires during five occasions: baseline 
(T1), 24 and 36 weeks of gestation (T2 and T3), and 4 and 12 weeks postpartum (T5 and 
T6). The questionnaires differ in composition at the five measurement moments, as shown 
in Table 1. During these occasions, participants are variably asked to report on anxiety 
symptoms (Dutch version of the State Trait Anxiety Inventory STAI), short and long version 
(49, 50)), depressive symptoms (the Dutch version of the Edinburgh Postnatal Depressions 
Scale; EPDS (51)), childhood trauma (Childhood Trauma Questionnaire; CTQ (52)), affect 
(the International Short-Form of the Positive and Negative Affect Schedule; I-PANAS-SF 
(53)), dysfunctional attitudes (Dysfunctional Attitude Scale; DAS (54)), medication beliefs 
(Beliefs about Medicines Questionnaire; BMQ (55)), medication adherence (Medication 
Adherence Rating Scale; MARS (56)) and Quality of Life (EQ-5D-5L (57)). Socioeconomic 
position, ethnicity, smoking behavior, alcohol use, family history and information on 
previous pregnancies and family size will be assessed using the Mind2Care questionnaire 
(58), a screen-and-advice instrument to detect mental health problems among pregnant 
women.  
Health care cost data is registered using the TIC-P (59). This instrument allows 
reliable recall over the past six months (60). We will adapt scoring for ‘normal’ 
absenteeism and sickness leave for pregnant and recently delivered women. Care will be 
taken for secondary effects on child-care for other children (if present) in case of 
postpartum hospitalization.  
Using the Discontinuation Emergent Signs and Symptoms checklist (DESS) (61), 
the discontinuation group will be monitored by telephone weekly during tapering, to 
collect information about dosages and potential symptoms of withdrawal. Both groups will 
receive telephonic monitoring of medication use, including psychiatric co-medication, at 
24 and 36 weeks of gestation (T2 and T3) and 4 and 12 weeks postpartum (T5 and T6).  
Alongside the self-report measures, several sources of biological materials will 
be collected during the study. At baseline, immediately after delivery and 12 weeks 
postpartum (T1, T4 and T6) we will collect maternal hair strands to measure cortisol levels. 
Hair cortisol is a validated biomarker for long-term cortisol exposure and makes it possible 
to create a timeline of cortisol exposure during follow-up (62). At baseline a maternal 
buccal swab will be collected in order to enable epigenetic and pharmacogenetic analysis. 
Maternal blood sampling will be performed 12 weeks postpartum (T6) to enable additional 
epigenetic and pharmacogenetic testing, but also for measurement of SSRI concentration 
and immunological factors.  
 
2. Health care professional 
We will send a Case Report Form (CRF) to the participant’s obstetric caregiver, either a 
midwife or a gynecologist, to request information about the pregnancy and delivery. 
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Complications during pregnancy and delivery, such as hypertensive disorders or 
pregnancy, fetal growth retardation, preterm labor, induced labor and caesarean section 
will be registered as well as information about the neonate (e.g. Apgar scores, birth 
weight, congenital malformations and admission to pediatric ward). 
 
Table 1. Assessment per measurement moment 
 Method T0 T1 T2 T3 T4 T5 T6 T7 
Clinical Diagnostic Interview (SCID-I) Int X  … … … … X  
Depressive symptoms (HDRS) Int X  … X … … X  
Peripartum depression (EPDS) SR  X X X  X X  
Anxiety (STAI) SR  X X X  X X  
Affect (I-PANAS-SF) SR  X X X  X X  
Attitudes (DAS) SR  X X X     
Daily hassles Int X  X X  X X  
Life events Int X  X X  X X  
Sociodemographic & -economic factors (M2C) SR  X       
Substance use (M2C) SR  X X X  X X  
Medication use Int X  X X  X X  
Medication adherence (MARS) SR  X X X  X X  
Medication beliefs (BMQ) SR  X       
Childhood trauma (CTQ) SR   X      
Quality of life (EQ-5D-5L) SR  X X X  X X  
Health care consumption (TIC-P) SR  X  X  X X  
Pregnancy related outcomes CG     X    
Neural development (GM) ME       X  
Child behavior (CBCL) SR        X 
Cortisol (hair strands) BM  X   X  X  
Buccal swab BM  X     X  
Blood sample BM       X  
Meconium (SSRI concentration) BM     X    
Breast milk (SSRI concentration) BM     X    
M2C = mind2care, Int = interview, SR = self-report, CG = caregiver, BM = biological materials, T0: pre-assessment, 
T1: baseline, T2: 24 weeks of gestation, T3: 36 weeks of gestation, T4: delivery, T5: 4 weeks postpartum, T6: 12 




At 12 weeks postpartum we will perform a General Movements (GM) assessment by taking 
video recordings at home (63). This assessment method evaluates the function of the young 
nervous system. 
GMs are spontaneous movements that are present from early foetal life onwards 
until the end of the first half-year of life. GMs are complex, occur frequently and last long 
enough to be observed properly. If the nervous system is impaired, GMs lose their 
complex and variable character and become monotonous and poor (64).  
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For mapping of the SSRI exposure of the newborn, samples of meconium and 
breast milk (if breastfeeding) will be collected. SSRI in meconium will be measured by a 
validated method according to LCH guidelines on LC-MS/MS (65). If feasible, hair strands 
and a buccal swab of the newborn will be collected at 12 weeks after birth (T6).  
Long-term follow-up includes the well-established, reliable and valid Child 
Behavior Check List 1.5-5 years, including the Caregiver Teacher Report Form (C-TRF) and 
the Language Development Survey (LDS) at 18 months postpartum (66). Also, permission 
will be asked to obtain routine data from Centers for Childhood (CJG) until 24 months (in 
particular on length gain, weight gain, normal development, and any information on 
abnormal behavioral development).  
 
Sample size 
Sample size calculation is based on the main aim of this study, which is to demonstrate 
non-inferiority of preventive CT with guided discontinuation of SSRIs (STOP) compared to 
continuation (GO), with respect to relapse or recurrence of a depressive episode up to 3 
months postnatal. We will use a non-inferiority margin (tolerance threshold, 'delta') of 15%. 
This is based on the assumption that this excess relapse (taking into account the possibility 
of restoring SSRI treatment) is still in balance with the expected beneficial effects of 
discontinuation of SSRI for the remaining mothers. We also anticipate that this balance is 
acceptable for women.  
With this non-inferiority margin, and the assumption that the overall absolute risk 
of relapse will be around 15% (67), we need 178 women, given alpha .025, power 80%, 
and a one-sided test. To account for some attrition, we aim to include 200 women in total. 
Given this sample size, we have sufficient power to demonstrate small to moderate effect 
sizes of .42 or over on continuous secondary outcomes. With respect to dichotomous 
secondary outcomes, we will be able to detect odds ratios of 1.5 or over when the base 
probability is .5. 
 
Statistical analysis  
Analysis will primarily be carried out according to the intention-to-treat principle, i.e. the 
participants will be analyzed according to their randomized allocation, regardless of the 
actual interventions received by the participant. Supplementary, we will perform analyses 
per protocol, i.e. according to actual SSRI use, irrespective of randomized arm.  
The primary outcome, risk (cumulative incidence up to 3 months postnatal) of 
relapse of depression, will be compared between the randomized groups. Differences 
will be assessed statistically using a one-sided Chi-Square Test at a significance level of 
.025 and will be presented as a risk difference. The remainder of statistical tests will be 
performed two-sided at a significance level of .05.  
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Time to relapse will be compared between the randomized groups using survival 
analysis. Kaplan-Meier curves will be constructed and differences will be tested using the 
log-rank test. A Cox proportional hazard model will be used to calculate hazard ratios 
Continuous outcomes, e.g. the General Movements scores at 3 months, will be 
compared between the groups using the unpaired t-test. Categorical secondary outcomes, 
e.g. obstetric complications, will be tested using Chi-Square Tests. For the continuous 
variables and categorical variables that are assessed more than twice, we will deploy linear 
mixed models and generalized linear mixed models respectively. These models use all 
available data (do not exclude persons with missing values) under the assumption of data 
being missing at random, and account for within-subject correlation over time. If despite 
randomization prognostically important factors differ between the groups, they will be 
adjusted for in supplemental analyses by including these factors in the pertaining 
regression models. 
Subgroup analyses will be undertaken according to: Dutch/non-Dutch, 
nulliparous/multiparous, yes/no history depressive disorder and/or anxiety disorder, 
yes/no co-morbid anxiety symptoms or disorder. All effect parameters will be supplied 
with a 95% confidence interval.  
 
Economic evaluation 
In the present study we will also evaluate the outcome in the two study groups (Stop and 
Go) from a societal, economic perspective. It is therefore important to weigh cost savings 
for both groups against their clinical value. If relapse/recurrence incidence is within the 
predefined threshold (15%), hence non-inferiority is confirmed; a straightforward cost 
minimization analysis will be executed focusing on cost savings. However, successful 
tapering of SSRIs will reduce SSRI use for years. Hence, with a sensitivity analysis on 
maternal effects and costs we will project cost estimations for 10 years. We expect that the 
upfront investment in PCT for women with previous psychiatric disorders will then be 
balanced by reduced SSRI use and less healthcare consumption. A previous RCT in a non-
pregnant population demonstrated that a brief CT intervention is cost effective in remitted 
depressed individuals that stop antidepressants, compared to continuation of 
antidepressants (68).  
If, however, relapse/recurrence incidence is higher than the predefined 
tolerance threshold, thus discontinuation is clinically inferior and rejected, a cost-
effectiveness analysis will be executed as primary analysis, which estimates the costs 
avoided per additional relapse. This is the opposite of the extra costs per prevented 
relapse, if the starting point would have been no SSRI, and starting SSRI would be 
considered. Regardless the relapse outcome, we will conduct a cost utility analysis which 
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estimates the impact of SSRI on the costs per Quality Adjusted Life Year (QALY), at least 




The use of SSRIs during pregnancy remains a clinical dilemma for both clinicians and 
patients. Given the increase of SSRI use among pregnant women and studies reporting 
conflicting results (7, 8, 11-14, 18, 19), there is dire need of randomized controlled trials 
investigating the use of SSRIs during pregnancy. This study will be the first to investigate 
the effect of preventive cognitive therapy with guided tapering of SSRIs from early 
pregnancy onwards as compared to continuation of SSRIs during pregnancy. Additionally, 
the study focuses on child outcomes and cost effectiveness.  
Previous studies on relapse prevention showed promising results for tapering 
antidepressants with added relapse prevention (29). Preventive cognitive therapy 
moreover showed promising long-term effects in non-pregnant women with a history of 
depression (27, 28). Preventive cognitive therapy with guided tapering of antidepressants 
may therefore be a good alternative for SSRI use during pregnancy. 
To our knowledge, no randomized controlled trials have been performed during 
pregnancy that investigated alternative treatment options versus SSRI use. This may be the 
result of the complex ethical situation of studies in pregnant women who are taking SSRIs 
and must be willing to either taper or continue SSRI use. Logistics of a nationwide 
randomized controlled trial are also difficult in a multidisciplinary setting. Although a 
multidisciplinary guideline exists, health care givers still have different views on best 
practice and therefore give different advices to their patients. This study will therefore be 
as pragmatic as possible, while still providing the intervention in a protocoled manner.   
Results of this study will be published and will contribute to further development of 
(international) guidelines. The results will provide a first step in giving pregnant women 
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Introduction: Antidepressant medication for prevention of depression recurrence in the 
perinatal period is common, but the efficacy remains unclear and it is unknown what risk 
factors may play a role. The objective of the current study was to structurally describe 
women who experienced a perinatal recurrence of depression despite ongoing 
antidepressant use. Additionally, this study aimed to identify clinically measurable risk 
factors for recurrence of depression. 
 
Methods: Eighty-five pregnant women with a history of depression who used 
antidepressants (e.g. SSRIs and SNRIs) at the start of the study were included. Clinical 
features, including information on psychiatric history and antidepressant use, were 
collected throughout the perinatal period (in this study defined as the period between 16 
weeks of pregnancy up till three months postpartum). For women experiencing recurrence 
of depression, these features were described in detail. To identify risk factors for 
recurrence of depression, we performed univariable logistic regression analyses. 
 
Results: Eight women (9.4%) experienced a recurrence of depression; two during 
pregnancy and six in the first 12 weeks postpartum. All women with recurrence of 
depression had first onset of depression during childhood or adolescence and had at least 
2 psychiatric co-morbidities. Identification of predictors for recurrence of depression 
yielded associations with depressive symptoms (EPDS score) around 16 weeks of 
pregnancy (OR 1.28, 95%CI 1.08-1.52), number of psychiatric co-morbidities (OR 1.89, 
95%CI 1.16-3.09) and duration of antidepressant use (OR 1.01, 95%CI 1.00-1.02). 
  
Conclusion: Implementing adequate risk assessment in women using antidepressants 
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INTRODUCTION 
Mental illness during the perinatal period, defined as the time period during pregnancy 
up to 3 months postpartum, is a common health problem (1), with approximately 25% of 
women experiencing any psychiatric disorder in this period (2). Perinatal depressive 
disorder is most common, with a recent meta-analysis observing a pooled prevalence of 
11.9% (3). Untreated perinatal depression is not only unfavorable for the mother; it is also 
associated with adverse outcomes in the offspring (4). Exposure to antenatal depressive 
disorder is associated with increased risks of premature delivery and low birth weight (5-
7) and behavioural, emotional, cognitive and motor problems in early childhood(8-10). 
Ante- and postnatal depression can furthermore influence the mother-infant relationship, 
posing increased risks for poor infant development (11-13).  
Therefore, prevention or treatment of perinatal depression is important. Several 
treatment options are available (14), but international guidelines differ in their 
recommendations (15) and clinicians are frequently noncompliant(16). Antidepressant 
medication is an increasingly used treatment option, either for prevention of recurrence 
of depression or as acute treatment in newly depressed patients (17-19). Perinatal 
prescription rates of antidepressants vary per study setting and range from 2.1% to 13.4% 
(17, 19-21).  
The preventive effect of continued antidepressant use in recovered women 
during the perinatal period remains unclear. A systematic review assessing the 
effectiveness of antidepressants for prevention of postnatal depression, based on 
observational studies, could not draw any clear conclusions due to low statistical power 
(22). Two studies with a naturalistic design followed women who continued or tapered 
antidepressants, from their first trimester throughout their pregnancy (23, 24). One study 
showed an increased risk of recurrence in women who discontinued their medication 
compared to women who continued their medication (68% vs. 26%) (23), the other study 
observed similar recurrence rates in women continuing or discontinuing antidepressants 
(16% in total) (24).  
From a clinical perspective, recognizing which pregnant women using 
antidepressants are at risk for recurrence is vital. With this knowledge, clinicians could 
more accurately identify and inform patients, and subsequently arrange additional 
guidance when necessary. Collectively these efforts could help promote the use of 
individualized patient-centered care, and potentially prevent negative effects in the 
offspring. The purpose of the current study was to structurally describe cases with perinatal 
recurrence of depression out of a group of women using antidepressants in their first 
trimester. Clinical features of the women with recurrence were inspected and reported. 





Setting and population 
The present study was embedded in an observational cohort and a randomized controlled 
trial (RCT) (Stop or Go) in the Netherlands (25). The Medical Ethical Committee of the 
Erasmus Medical Center approved this study (MEC-2014-505).  
Women were recruited during their prenatal booking visit in midwifery practices 
and hospitals, through general practitioners, or through advertisement in (social) media. 
When an eligible woman was identified, study researchers gave counselling about the 
RCT and observational cohort. Written informed consent was necessary for participation. 
For the present study, participants were considered eligible if they (1) were less 
than 16 weeks pregnant, (2) used a Selective Serotonin Reuptake Inhibitor (SSRI), Selective 
Serotonin and Noradrenalin Reuptake Inhibitor (SNRI) or Tricyclic Antidepressant (TCA), 
(3) had a history of at least one depressive episode as assessed by the Structured Clinical 
Interview for DSM-IV Axis I Disorders (SCID-I) (26), and (4) did not have a current 
diagnosis of depression according to the SCID-I. Women without sufficient proficiency in 
Dutch or English were excluded. Participants were recruited between April 2015 and 
February 2018. 
 
Perinatal recurrence of depression 
We assessed relapse and recurrence, further referred to as recurrence of depression, as 
defined by the SCID-I, during pregnancy and up to 12 weeks postpartum. The SCID-I was 
assessed before 16 weeks of pregnancy (baseline assessment) and 12 weeks postpartum.  
 
Clinical features of women with recurrence of depression 
Clinical features including information on psychiatric history and antidepressant use were 
documented. SCID-I DSM-IV diagnoses, age of first and last onset of depression, number 
of depressive episodes, history of psychiatric hospital admission, psychiatric family history, 
antidepressant prescriber, current antidepressant dosage and number of previous 
discontinuation attempts were all determined before 16 weeks of pregnancy (baseline 
assessment).  
The Edinburgh Postnatal Depression Scale (EPDS) was administered at baseline, 
24 and 36 weeks of pregnancy and 4 and 12 weeks postpartum for the assessment of 
depressive symptoms (27, 28). The Beliefs about Medicine Questionnaire, specific version 
(BMQ-s) was administered at baseline (29). The BMQ-s consists of two scales assessing (1) 
personal beliefs about the necessity of prescribed medication for controlling one’s illness 
(score range 5-25) and (2) concerns about the potential adverse consequences of taking 
medication (score range 6-30). Higher scores indicate stronger beliefs in the concepts of 
Recurrence of depression in the perinatal period 
 115 
the scale. During follow-up, data on healthcare use was collected using the Trimbos/iMTA 
questionnaire for Costs associated with Psychiatric Illness (TIC-P) for number of visits to 
the general practitioner (GP), psychiatrist, psychologist, psychiatric nurse, psychotherapist 
and mental health care practice assistant (30).   
 
Predictors of depression recurrence 
Potential predictors for recurrence focused on sociodemographic characteristics, illness 
(history) and antidepressant specifications. 
Included participant characteristics were age, level of education, having a paid 
job, parity and planned pregnancy (yes/no). Level of education was categorized in low 
(primary/secondary education) and higher education.  
Included illness (history) determinants were EPDS score around 16 weeks of 
pregnancy, number of depressive episodes, number of axis I psychiatric co-morbidities 
(both past and present) as measured with the SCID-I and a history of psychiatric hospital 
admission. 
Antidepressant specifications included duration of antidepressant use, number 
of previous tapering attempts, and dose equivalency in early pregnancy. Dose equivalency 
was calculated by dividing the prescribed dosage by standard initial dosages, which are: 
citalopram 20mg, escitalopram 10mg, fluoxetine 20mg, fluvoxamine 100mg, paroxetine 
20mg, sertraline 50mg and venlafaxine 75mg. Standard dosages were based on American 
and Dutch pharmaceutical treatment guidelines (31, 32). During prospective follow-up, 
tapering and discontinuation was reported and divided into three categories: (1) no 
tapering, (2) intention to taper, but did not completely discontinue antidepressants during 
follow-up and (3) participant completely discontinued antidepressants at any point during 
follow-up, whether or not this discontinuation afterwards persisted throughout follow-up. 
 
Statistical analysis 
We performed a case-series study describing individual characteristics of participants. 
Additionally, univariable analyses were used to qualify associations between recurrence 
and potential predictors (previous section). We used logistic regression analyses with 
recurrence as the outcome variable and the predictors entered one at a time as 
independent variables. All associations were expressed as odds ratios (OR) with 95% 































A total of 477 pregnant women were referred for further counselling for both the RCT and 
the observational cohort. Thirty-one women (6.5%) were unreachable for counselling, 44 
(9.2%) decided to participate in the RCT and 247 (51.8%) declined to participate in both 
trials. Of the remaining 155 women willing to participate in the observational cohort, 
another 70 (14.7%) were excluded for the current study: six had an incomplete baseline 
record, 49 did not have a history of depressive disorder, two were currently depressed, 
three had a miscarriage and ten were lost to follow-up. This resulted in a total sample of 
85 women (see figure 1).  
Table 1 illustrates the characteristics of all participants, including those with and 
without depression recurrence. Eight women (9.4%) experienced a perinatal recurrence 
of depression, none experienced relapse. Overall, mean age was 31.7 years (SD 4.1), 
over half had a high level of education and for 50% it was their first pregnancy. Of all 85 
women, 44 (51.8%) had one previous depressive episode and 7.1% had more than 3 
episodes. Psychiatric co-morbidity was present in 71.8% of women, with panic disorder 
Referred for counseling (n=477) 
Screened for eligibility (n=446) 
Remaining sample (n=155) 
Final study sample (n=85) 
Excluded: unreachable (n=31) 
Excluded (n=291) 
- Participated in RCT (n=44) 
- Declined to participate (n=247) 
Excluded (n=70) 
- Incomplete baseline record (n=6) 
- No history of depression (n=49) 
- Current depressive episode (n=2) 
- Miscarriage (n=3) 
- Loss to follow-up (n=10) 
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and agoraphobia most common (both 24.7% of participants). Overall, the median duration 
of antidepressant use was 60 months, in which a limited number of tapering attempts were 
undertaken; 81.0% either did not try or only once attempted to discontinue their 
antidepressants. During follow-up, 12 women (14.1%) completely discontinued their 
medication and four (4.7%) intended to taper medication, but did not completely 
discontinue during follow-up.  
 
Women with perinatal recurrence of depression 
Out of eight women with a recurrence, six experienced recurrence after childbirth. Three 
of the women discontinued antidepressants during follow-up. A visual representation of 
timing of onset of recurrence can be seen in figure 2. Clinical features of individual women 
are listed in Table 2 (case numbers correspond with case numbers in figure 2). The mean 
age at first onset of depression was 16 years. None of these women had a previous 
episode with postpartum onset (for six women this was their first pregnancy). Four women 
had a positive family history of psychopathology; case 2 had a father with depression and 
obsessive-compulsive disorder, case 3 a brother with attention-deficit hyperactivity 
disorder and antidepressant use, case 7 a cousin who committed suicide and case 8 a 
mother, aunt and grandma with depression. All women had two or more psychiatric co-
morbidities, mostly anxiety disorders. Most women received their medication through the 
general practitioner (GP). Overall, beliefs about necessity of their medication (BMQ-
necessity) was high. However, the women with the lowest scores were also the women that 
discontinued their antidepressants during follow-up. The beliefs about adverse 
consequences were mild and homogeneous. All women had a history of (added) non-
pharmacological treatment, receiving therapy for multiple years including cognitive 
therapy. Three women still received non-pharmacological therapy in early pregnancy.  
 All eight women visited the GP on average four times during study follow-up. 
Women had several psychiatric healthcare professionals. Five women visited a psychiatrist 
(mean number of visits 4.2), four a psychologist (mean number of visits 7.8), four a 
psychiatric nurse (mean number of visits 10.8), four a mental health care practice assistant 
(mean number of visits 2.0) and two a psychotherapist (mean number of visits 5). Case 7 
only visited her GP (four times in total). The other women visited at least one more 
healthcare professional (range 1-5). 
During pregnancy, the mean EPDS scores of the eight women remained stable 
(11.6, 12.1 and 11.1 consecutively), but increased after childbirth, when six women had 
onset of recurrence. Mean EPDS scores four weeks postpartum were 16.3 and 15.3 at 12 
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Predictors of perinatal recurrence of depression 
Univariable associations between the independent determinants and recurrence of 
depression are presented in Table 1. A higher EPDS score around 16 weeks of pregnancy 
(OR 1.28, 95%CI 1.08-1.52), a higher number of psychiatric co-morbidities (OR 1.89, 
95%CI 1.16-3.09) and a longer duration of antidepressant use (OR 1.01, 95%CI 1.00-1.02) 
were associated with an increased risk of recurrence. 
 
 
Figure 2. Survival curve of women with recurrence of depression in the perinatal period 
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Figure 3. Edinburgh Perinatal Depression Scale (EPDS) sumscore in the perinatal period 
 
Each line represents a case with recurrence of depression. Case numbers match with case numbers listed in table 




In this prospective cohort study, 85 pregnant women with a history of depression and 
baseline antidepressant use were assessed for depression recurrence. In total, eight 
women (9.4%) experienced a recurrence of depression at follow-up. All women with 
recurrence had experienced their first onset of depression during childhood/adolescence 
and had at least two psychiatric co-morbidities. Due to the low rate of recurrence, we were 
only able to identify univariable predictors of recurrence. Results yielded associations for 
recurrence with depressive symptoms around 16 weeks of pregnancy, number of 
psychiatric co-morbidities and duration of antidepressant use.  
 
Two previous observational studies investigated recurrence rates of depression in women 
using antidepressant during pregnancy and reported rates ranging from 68 to 16% (23, 
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period. Of the women discontinuing, 25% experienced recurrence compared to 7% of 
the women continuing. A possible explanation may be the difference in study populations. 
Cohen et al. (23) included women through psychiatric institutes and reported that 76.6% 
had three or more previous depressive episodes. In the Yonkers study (24), 38% of the 
women had four or more previous depressive episodes, compared to 7.1% in our 
population. Number of previous episodes in the general population is one of the strongest 
predictors for recurrence (33). Another explanation is that both previous studies reported 
most women had onset of recurrence in the first trimester (23, 24), whereas in our study, 
women with onset of recurrence in the first trimester (at start study) were excluded.  
During follow-up, 14% of women completely discontinued their medication. This 
rate is in accordance with Dutch discontinuation rates during pregnancy as recorded in 
insurance and pharmacy databases (19, 34). Similar to Yonkers et al. (24), we did not find 
a significant effect of antidepressant discontinuation on recurrence risk.  
There were some noticeable details regarding the women with recurrent 
depression. All eight women had a first onset of depression during childhood or 
adolescence, and all but one of the women had multiple depressive episodes. Age of first 
onset has been associated with risk of recurrence, although it is difficult to disentangle the 
effect of age of first onset from the number of depressive episodes, as these two are highly 
correlated (35). This early-onset depression has previously been associated with a more 
severe and chronic course of depression, often affecting women, with a longer duration 
of illness, more episodes, higher symptom severity, more psychiatric co-morbidity and 
more tendency to attempt suicide (36, 37). 
  Number of visits to psychiatric health care professionals during study follow-up 
ranged between 0 and 26 in all cases. Two women did not receive any, or only very 
limited, additional psychiatric healthcare, indicating that they did not receive adequate 
treatment for their recurrent depressive episode. This is unwanted as a review of 23 
longitudinal studies found that 38% of mothers with postpartum depression (PPD) 
continued to have major depression during their child’s first year of life and even beyond, 
with previous history of depression as a predictor for a chronic course of PPD (38), 
affecting the child as well (39). Ideally, all women would be offered additional care, even 
before recurrence takes place, as a recent study among adults showed that adding 
preventive cognitive therapy to antidepressant treatment resulted in a 41% relative risk 
reduction of relapse or recurrence of depression compared with antidepressants alone 
(40).  
The analyses identified three predictors for recurrence: depressive symptoms 
around 16 weeks of pregnancy, number of psychiatric co-morbidities and duration of 
antidepressant use. In early pregnancy, five women already had an EPDS score above cut-
off (27), although they did not fulfil the SCID-I criteria yet for depressive disorder. The 
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EPDS consists of ten questions and can thus be easily assessed in early pregnancy. 
International clinical guidelines encouraging routine screening for perinatal depression 
have been available for over a decade (41). Previous validation research of the EPDS 
found that a cut-off value of 11 in the first trimester, and ten in the second and third 
trimesters gave the most adequate combination of sensitivity, specificity, and positive 
predictive value (27). Clinicians may use these cut-off scores to initiate and monitor 
additional treatment, to prevent recurrence and decrease current symptoms of depression. 
The second predictor was number of psychiatric co-morbidities. Psychiatric co-morbidity 
has been associated with shorter time to recurrence in a non-pregnant population (42). 
During pregnancy, clinicians should therefore assess presence of psychiatric co-
morbidities, and determine whether additional treatment targeting these co-morbidities is 
necessary. Lastly, a longer duration of antidepressant use was associated with recurrence. 
Longer duration indicates maintenance treatment, which is recommended for patients with 
three or more depressive episodes by international guidelines (43). However, the clinical 
relevance of the increased risk (OR 1.01) remains to be determined. 
 
Strengths and limitations 
A strength of the current study is that recruitment of participants took place in various 
settings (hospitals, midwifery practices, GP’s and social media), ensuring recruitment of 
a representative sample. Detailed information was gathered prospectively, thereby 
preventing recall bias and providing insight into this specific population across the 
perinatal period.  
However, several limitations should be noted. Due to the inclusion and exclusion 
criteria, only women with recurrence of depression after the first trimester were included, 
limiting our sample size and thereby the number of recurrences. Other vulnerable groups 
of women, e.g. women with a history of depressive disorder who discontinue 
antidepressants before pregnancy, were not observed. In the Netherlands approximately 
40% of women discontinue antidepressant treatment in the year before pregnancy and 
even higher figures are reported in other countries (19). In the current study, women who 
discontinued antidepressants before pregnancy were excluded. To fully examine safety of 
antidepressant discontinuation, future studies should also include women discontinuing 
antidepressants before pregnancy. Another limitation is the limited number of women 
discontinuing their medication. To specifically examine the effect of discontinuation on 
recurrence rates, it would have been preferential to include more women discontinuing 
antidepressants, for example by oversampling this group. Lastly, women lost to follow-up 
(n=10) were excluded from the current study as information on recurrence was missing. 





Conclusion and future recommendations 
The current study presented descriptive data on a prospective cohort of pregnant women 
with antidepressant use in early pregnancy and a history of depressive disorder. Three 
predictors for recurrence of depression were identified: depressive symptoms in early 
pregnancy, number of psychiatric co-morbidities and duration of antidepressant treatment. 
Importantly, if future studies can more robustly establish the predictive value of these 
variables they could easily be assessed as part of routine care procedures by clinicians. 
Implementing adequate and accessible risk assessment in daily practice can lead to 
improved individualized patient-centered care. No effect of discontinuation of risk of 
recurrence was observed, however, the proportion of women discontinuing medication 
was small and results should therefore be interpreted with caution. Future studies should 
aim to define additional predictors for recurrence of depression in pregnancy, assess the 
effects of implementing screening instruments during this phase and evaluate the effect of 
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Introduction: Intrauterine exposures such as maternal psychopathology and stress are 
known to influence the physical and mental health of the offspring. One of the proposed 
pathways underlying these associations is dysregulated hypothalamic-pituitary-adrenal 
(HPA) axis activity in the offspring. This study examined the relation of perinatal maternal 
symptoms of psychopathology and stress with offspring HPA axis activity at 6 years as 
measured by hair cortisol and cortisone concentrations. 
 
Methods: The study was part of the population-based Generation R Study, a prospective 
population-based cohort from fetal life onwards. 2,546 children and their mothers formed 
the study population. Perinatal maternal psychopathology and stress were assessed by 
questionnaires in the second and third trimester. Principal components for both 
psychopathology and stress were created to reduce the number of explanatory variables. 
Child hair samples for cortisol and cortisone measurements were collected at the age of 
6. Linear regression analysis, adjusted for covariates, was used to examine associations 
between maternal psychopathology and stress and child hair cortisol and cortisone levels. 
 
Results: The maternal psychopathology principal component was associated with higher 
child hair cortisone (adjusted B = 0.24, 95%CI 0.08;0.40, p-value < 0.01). Effect 
estimates of the individual dimensions ranged from 0.97 (95%CI 0.21;1.73, p-value = 
0.01) for interpersonal sensitivity to 1.67 (95%CI 0.86;2.47, p-value < 0.01) for paranoid 
ideation. In addition, children exposed to intrauterine stress, as measured by the principal 
component, had higher hair cortisone levels (adjusted B = 0.54, 95%CI 0.21;0.88, p-
value < 0.01). Exposure to maternal psychopathology and stress was not associated with 
offspring hair cortisol. 
 
Conclusion: Our results suggest that maternal psychopathology and stress during 
pregnancy are associated with long-term HPA axis activity of the offspring. The association 
of maternal psychopathology and stress during pregnancy with offspring hair cortisone 
levels is a novel finding. Future studies should examine whether these psychophysiological 
differences between exposed and non-exposed children underlie offspring morbidity 











Many intrauterine exposures are known to influence the physical and mental health of the 
offspring (1, 2). Maternal psychopathology and stress during pregnancy are among the 
most common intrauterine exposures associated with a negative impact on the offspring’s 
health (3, 4). Exposure to maternal psychopathology or stress during pregnancy is 
associated with preterm birth and low birth weight (5). In the long-term, maternal 
psychopathology or stress during pregnancy is related to behavioral, emotional, cognitive 
and motor problems in childhood (6, 7) and psychiatric disorders in adolescence (8, 9). 
Research examining the origins of these associations led scientists to propose models such 
as the ‘fetal programming hypothesis’ (10) or the ‘developmental programming 
hypothesis’ (2). According to these programming hypotheses, the fetus or infant adapts 
as a response to the health and physical state of the mother, thereby altering important 
physiological and metabolic processes that can endure into adulthood. The hypothalamic-
pituitary-adrenal (HPA) axis is one of the major candidate systems that could be altered by 
adverse intrauterine exposures, especially since plasticity of the HPA axis is high during 
early fetal development (11, 12).  
 The HPA axis is the biological stress system that protects the human body from 
deleterious effects of acute stress. Cortisol, the end product of the HPA system, is often 
used to investigate HPA axis reactivity, especially in studies on psychological stress. There 
are several conventional methods to measure cortisol, such as saliva, blood or urine 
samples. These measures reflect cortisol levels at the time of sampling and are all highly 
influenced by daily fluctuations due to circadian rhythms and fluctuations based on 
homeostatic regulation (13), potentially creating methodological problems associated with 
collection. Conventional measures therefore reflect a ‘snapshot’ of HPA axis activity and 
may not be the most informative measure in the evaluation of long-term HPA axis activity. 
An increasingly used non-invasive method for detecting differences in individual’s long-
term stress levels is hair cortisol analysis (14-16). Cortisol extracted from hair samples 
reflects accumulated concentrations and can therefore give a more stable and long-term 
indication of HPA axis activity than saliva, blood or urine collection. Hair grows with 
approximately 1 centimeter per month (17), enabling assessment of mean cortisol 
concentrations of the last couple of months (18). Previous research showed that hair 
cortisol is most strongly associated with the prior 30-day integrated cortisol production 
measure (19), or three-day average of single-day salivary level (20), both supporting the 
notion that hair cortisol reflects long-term cortisol levels. Low to moderate correlations with 
short-term levels as single-point saliva cortisol levels were observed (20).  
With the introduction of liquid chromatography tandem-mass spectrometry (LC-
MS/MS) (21), the additional quantification of cortisone in scalp hair has become possible, 
which is metabolized from cortisol in the peripheral tissues by the 11ß-hydroxysteroid-
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dehydrogenase enzyme type 2 (11ß-HSD-2), where it might act as reserve capacity for 
cortisol. Adding cortisone in parallel to cortisol may give even more insight into the 
cumulative amount of active and inactive corticosteroids in the body. Previous research 
showed elevated hair cortisone concentrations in young children under psychosocial stress 
(15). Another study even suggests salivary cortisone can provide a better reflection of 
systemic cortisol levels than salivary cortisol (22).  
A limited number of studies have related maternal psychopathology and stress 
during pregnancy to changes in HPA axis functioning in the offspring, mostly in the first 
year of life. Maternal feelings of stress and anxiety in the last trimester of pregnancy have 
been measured in a prospective longitudinal study and assessed infant cortisol reactivity, 
measured through saliva, at 5 and 8 weeks and at 5 and 12 months of age (23); higher 
infant cortisol reactivity was observed in children exposed to intrauterine anxiety. Antenatal 
depression was analyzed in another prospective study that examined the association with 
infant cortisol reactivity at 2 months of age and found that infants exposed to both low and 
high levels of maternal depression showed greater cortisol reactivity (24). However, 
whether symptoms of psychopathology and stress during pregnancy affect long-term HPA 
axis activity in the offspring is largely unknown. 
The objective of the current study was therefore to investigate whether maternal 
psychopathology and stress during pregnancy are associated with offspring HPA axis 
activity at 6 years of age. We examined several dimensions of psychopathology, including 
depression and anxiety, as well as different forms of experienced stress during pregnancy 
such as stressful life events and pregnancy-related anxiety. For long-term HPA axis activity 
we measured both hair cortisol and the novel biomarker hair cortisone when children were 
6 years of age. We hypothesized, in line with previous short-term findings, that maternal 
symptoms of psychopathology and stress during pregnancy are related to heightened 




Setting and population 
The present study was embedded in an on-going population-based cohort, the Generation 
R Study, designed to identify early environmental and genetic causes and causal pathways 
leading to normal and abnormal growth, development and health from fetal life, childhood 
and young adulthood (25). In total, n=8880 mother were enrolled during pregnancy with 
deliveries from April 2002 to January 2006. The Medical Ethics Committee of the Erasmus 
Medical Centre, Rotterdam, approved the study. Written informed consent was obtained 
from all participants.  
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For the present explorative analysis, only children who participated in the pre- 
and postnatal follow-up (n=7,510) were considered (Figure 1). Of these, 1,457 children 
were excluded, as they did not visit the research center in childhood, when hair samples 
are collected. Information on maternal psychopathology and stress parameters was missing 
in 338 children. Hair collection did not start immediately at onset of this data collection 
wave and 3,161 children were not approached. The response rate for children that were 
approached for hair collection was 85% (26). Cortisol concentration could be quantified 
in 2,523 children and cortisone in 2,485 children. Extreme outliers, defined as cortisol or 
cortisone levels > 4SD (standard deviation), indicating contamination, were excluded. 
Thus, n=2,546 formed the final study population for analysis.  
 
Maternal psychopathology 
In the second trimester (at 20-25 weeks of gestation), the Brief Symptom Inventory (BSI) 
was administered. The BSI is a validated 53-item (5-point scale) self-report symptom 
inventory outlined to ascertain the psychological state of individuals in the preceding 7 
days (27, 28). The BSI has nine dimensions designed to assess individual symptom groups. 
For this study, we used the Global Severity Index (GSI), the overall mean designed to help 
quantify a patient’s severity-of-illness. In addition, we used the specific dimensions of the 
BSI: somatization, obsessive-compulsivity, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation and psychoticism. The scores for the GSI and 
each dimension separately are calculated by dividing the sum of all items by the number 
of items. Sum scores per subscale therefore range from zero to four, with a higher score 
indicating more symptoms on that specific subscale.  
 
Maternal stress 
Multiple questionnaires were administered in the second and third trimester to measure 
different dimensions of stress, including stressful life events, long lasting difficulties, family 
functioning and pregnancy related stress. The Dutch-adapted version of the Social 
Readjusting Rating Scale (SRRS) was administered to assess the occurrence of repeated 
stressful life events in the preceding 12 months (29). The SRRS consists of 10 yes/no 
questions and items each have a certain amount of life change units (LCU). The sum score 
is the total of LCU’s. The Long Lasting Difficulties Questionnaire (LLDQ) was administered 
for measurement of financial, health or social problems in the preceding 12 months (30). 
We used an adjusted version of the Dutch LLDQ consisting of 12 items that are scored on 
a 5-point scale. Maximum score per item is 3, leading to a sum score between 0 and 36. 
The Family Assessment Device (FAD) was administered to evaluate dimensions of family 
function (31). In this study, we applied the General Family functioning subscale, which 
consists of 12 items rated on a 4-point scale. This subscale assesses the overall health and 
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pathology of the family. The sum score is the mean of the items scores and therefore has 
a value between 1 and 4. A score above 2.17 is seen as pathological. To measure 
stress/anxiety concerning the pregnancy and the baby, a Dutch adapted version of the 
Pregnancy Outcome Questionnaire (POQ) was administered consisting of 13 items, rated 
on a 4-point scale, with a maximum score of 3 per item (32). The sum score is the mean 
of the item scores and is therefore a value between 0 and 3.  
 
Hair cortisol/cortisone 
For extraction of hair cortisol and cortisone, hair samples of approximately 100 strands 
were cut from the posterior vertex using small surgical scissors, as close to the scalp as 
possible. Hair locks were then taped to a piece of paper with the scalp end marked, and 
stored in an envelope at room temperature until further analysis. Briefly, the proximal 3 cm 
of hair samples were weighed using an electrical scale and minced. Hair samples were 
then washed in LC-grade isopropanol for 2 minutes at room temperature, and left to dry 
for at least 2 days. Deuterium labeled cortisol and cortisone were added prior to extraction. 
Extraction was performed using LC-grade methanol for 18 hours at 25° Celsius, in a gently 
shaking water basin. The extract was then transferred to a glass tube, centrifuged at 4300 
g (gravity), and evaporated to dryness at 37° Celsius under a constant flow of N2. After 
reconstitution in 1 ml 2% LC-grade methanol, the extract was loaded on an offline solid 
phase extraction plate (HLB Oasis 96-well SPE plate, Waters Chromatography), washed 
with 1 ml 30% LC-grade methanol, and eluted twice in 300 μl 100% LC-grade methanol. 
The extract was then evaporated to dryness at 50° Celsius under a constant flow of N2 and 
stored at 4° Celsius until further analysis. Prior to analysis, the samples were reconstituted 
in 100 μl eluent (running fluid), mixed using a vortex mixer, and analyzed using LC-
MS/MS (Xevo TQS, Waters Chromatography) (33). 
 
Covariates 
Potential covariates were selected based on prior research (23, 24, 33). Age, marital 
status, parity, gender child, ethnicity, hair color of child, education, family income, 
number of persons in a household and alcohol and smoking behavior were based on self-
report. Marital status was dichotomized into ‘married, registered partnership or living 
together’ versus ‘no partner’. Maternal ethnicity was categorized according to the 
classification of Statistics Netherlands (34, 35). Educational level was categorized in three 
levels: primary, secondary and higher education (35). Family income was defined as the 
total net monthly income of the household, categorized as less than €1200 (US $1551) 
(below social security level), €1200 to €2000 (US $1551-US $2586), and more than 
€2000 (US $2586) (more than modal income). Information about maternal prenatal 
alcohol use and smoking was based on questionnaires in each trimester. 




First, descriptive statistics of the study population were provided. Data was explored using 
histograms and calculating correlations between the different psychopathology and stress 
measures. The correlation of the subscales of the BSI were moderately to strongly 
correlated (0.45 < r < 0.78), while the stress parameters (SRRS, LLDQ, FAD and POQ) 
during pregnancy only showed weak to moderate correlations (0.15 < r < 0.37). Hair 
cortisol and cortisone measurements showed a strong correlation (r = 0.66).  
To reduce the number of explanatory variables tested, we performed principal 
component analysis (PCA) in two groups: psychopathology (BSI subscales) and stress 
(SRRS, LLDQ, FAD and POQ). PCA is a statistical technique to convert a set of observations 
of possibly correlated variables into a set of values of linearly uncorrelated variables called 
principal components. To check if we can factorize the original variables efficiently we 
used the Bartlett’s sphericity test and the Kaiser-Mayer-Olkin index. Both indicated our data 
was suitable for PCA. Subsequently, we performed principal component regression with 
the retrieved principal components with an eigenvalue above one. For the 
psychopathology group, one principal component was retrieved with component loadings 
of the items between 0.74 and 0.90. For the stress parameters, one principal component 
with item loadings between 0.64 and 0.80 was retrieved. Only when an association 
between the principal component and outcome variable was observed (as defined by a p-
value <0.05), linear regression analysis was used to examine the relations of the individual 
psychopathology and stress measures with the outcome variable as to further examine the 
contribution of each individual measure.  
Based on the 5% change-in-estimate (36), we corrected for the following 
confounders: marital status, parity, ethnicity, education, family income, number of people 
in a household and alcohol behavior. The other covariates, namely age, gender child, hair 
color of child and smoking behavior, did not reach a 5% change-in-estimate. On average, 
4.5% of data across the covariates was missing. To avoid complete case analysis bias, we 
accounted for missing information on the confounders (determinants and outcomes were 
not imputed) by using multiple imputation methods. As recommended, imputations were 
based on the relations between all variables in the study (37). We report only the pooled 
estimates of the analysis of the 10 imputed datasets. Analysis with non-imputed data gave 
similar results compared to the imputed dataset. Statistical Package for Social Sciences 































*Hair collection did not start immediately at onset of this research wave. The response rate for children asked for 







Children participating in pre- and 
postnatal follow-up (n=7,510) 
Research center visit (n=6,053) 
Research center visit missing 
(n=1,457) 
Information on maternal 
parameters available (n=5,715) 
Maternal parameters missing 
(n=338) 
Hair sample missing* (n=3,161) 
Cortisol or cortisone level >4SD 
(n=8) 
Study sample (n=2,546) 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   





Prenatal and postnatal characteristics of the study population are shown in table 1. Mean 
age of women at study inclusion was 30.5 years and the majority of women were 
primigravida. Due to the urban character of the study, a variety of ethnicities were present, 
with a little over half of the participants being Dutch. About half of the population had a 
higher education (48.5%). Median symptoms of psychopathology and stress during 
pregnancy were low, as to be expected in a population-based study. 
 
Prenatal exposure to psychopathology and stress and child hair cortisol 
The analysis of the maternal psychopathology principal component initially showed an 
association with child hair cortisol levels (B = 0.17, 95%CI 0.05;0.29, p-value < 0.01). 
However, this association was largely explained by confounding factors (adjusted B = 
0.11, 95%CI -0.02;0.24, p-value = 0.10). The same was observed for the maternal stress 
principal component: the unadjusted association of the maternal stress principal 
component with child hair cortisol (B = 0.33, 95%CI 0.09;0.56, p-value < 0.01) attenuated 
after adjustment for confounders (adjusted B = 0.23, 95%CI -0.05;0.51, p-value = 0.11).  
 
Prenatal exposure to psychopathology and stress and child hair cortisone 
Table 2 demonstrates the results of the linear regression models of maternal 
psychopathology and stress during pregnancy and child hair cortisone levels. There was 
an association of overall maternal psychopathology during pregnancy with child hair 
cortisone (B = 0.22, 95%CI 0.10;0.34, p-value < 0.01), which remained present after 
adjustment for confounders (adjusted B = 0.18, 95%CI 0.05;0.31, p-value < 0.01). 
Additionally, table 2 shows that effect estimates of the different maternal psychopathology 
scales during pregnancy and child hair cortisone ranged from 0.54 (95%CI -0.02;1.10, 
p-value = 0.06) for obsessive-compulsive symptoms and child hair cortisone to 1.28 
(95%CI 0.39;2.16, p-value < 0.01) for psychoticism and child hair cortisone.  
 The stress principal component was also associated with child hair cortisone, 
both before (B = 0.50, 95%CI 0.26;0.73, p-value < 0.01) and after adjustment for 
confounding factors (adjusted B = 0.51, 95%CI 0.23;0.79, p-value < 0.01). Subsequent 
analysis of all individual stress measures in relation to child hair cortisone pointed out that 
the association was largely driven by long-lasting difficulties (adjusted B = 0.18, 95%CI 







In this population-based study, we found that maternal symptoms of psychopathology 
during pregnancy were associated with hair cortisone levels in children 6 years of age. 
Higher levels of symptoms on different psychopathology subscales prenatally were 
associated with increased levels of child hair cortisone. Additionally, we found an 
association of maternal symptoms of stress during pregnancy, in particular long-lasting 
difficulties, with child hair cortisone. In contrast, the exposure to maternal symptoms of 
psychopathology and stress during pregnancy was not related to child hair cortisol levels. 
However, the direction of the effect on cortisol, while not significant, was similar to that of 
cortisone. 
 
Previous studies examining exposure to prenatal psychopathology and stress and child 
HPA axis functioning mostly use salivary cortisol, which is more susceptible to daily 
fluctuations than the hair cortisol measurement used in the present study. These prior 
studies have shown higher cortisol levels in children exposed to intrauterine 
psychopathology (24, 38). For example, a prospective study performed among 133 infants 
in India showed infants exposed to the highest levels of maternal depressive symptoms 
during intrauterine life had elevated salivary cortisol responses to immunization at 2 
months of age (24). Another study among 29 mother-child pairs showed children whose 
mothers had pregnancy specific anxiety showed higher levels of salivary cortisol on school 
days at 5 years of age (38). Contrary to our expectations that were based on prior literature, 
we found no associations of prenatal maternal psychopathology and stress with hair cortisol 
levels in children 6 years of age. The discrepancy could originate from the difference in 
measurement method of cortisol. Salivary cortisol reflects the level at the time of sampling. 
In both prior studies (24, 38), cortisol was measured after induction of a stressor to 
measure the stress response reaction. Cortisol assessed from hair samples is a more stable 
long-term stress indicator, not dependent on stressors during sampling (16). Possibly, 
intrauterine exposure to maternal psychopathology and stress influences the immediate 
stress response but not long-term (basal) cortisol levels.  
 As expected, higher levels of hair cortisone in children exposed to intrauterine 
psychopathology and stress were observed in the present study. Especially long-lasting 
difficulties were associated with child hair cortisone levels, indicating that chronicity of 
stress might have a greater influence than other forms of stress such as single stressful 
events. Interest in the use of hair cortisone as an additional biomarker to cortisol for 
psychopathology and stress has recently increased. Cortisone, conversed from cortisol by 
the 11ß-hydroxysteroid-dehydrogenase enzyme type 2, has been shown to be higher than 
cortisol in hair of children (39), just as in our study, and might therefore be a more 
sensitive measure of HPA axis activity than cortisol. For example, one previous prospective 
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cohort study has examined the influence of stress in children on hair cortisone levels (15). 
Hair cortisone levels of 168 elementary school girls (5 to 10 years old) were measured 
and child-reported stress was obtained through questionnaires. Associations of increased 
hair cortisone and concurrent stressful events were observed. Another recent study among 
62 pregnant women evaluated the association between maternal symptoms of depression, 
somatization and stress and maternal hair cortisol and cortisone levels and observed 
stronger associations with hair cortisone than with hair cortisol (40). To our knowledge, 
there are no studies that examined intrauterine exposure to maternal psychopathology and 
stress and influence on child hair cortisone levels. An explanation for our findings – 
increased cortisone levels but an absence of increased cortisol levels – is therefore not 
readily available. Further research has to examine influence of 11ß-HSD-2 activity and 
corticoid binding globulin (CBG) levels or affinity resulting in different concentrations of 
free corticosteroids and thus influencing incorporation of cortisol and cortisone into hair 
from the bloodstream. 
 
Mechanisms of HPA axis alteration 
The exact underlying mechanisms of HPA axis alteration in the offspring are still unclear, 
although previous studies have attempted to examine potential pathways involved. The fetal 
programming hypothesis suggests that the fetus responds to intrauterine exposure, in this 
case psychopathology or associated high levels of maternal cortisol, with altered 
physiological and metabolic processes as preparation for the anticipated postnatal 
environment (10). High levels of maternal cortisol reaching the fetus could either be the 
result of extreme maternal stress, overriding the capacity of placental 11ß-HSD-2 to convert 
cortisol into the inactive metabolite cortisone and thereby accumulating cortisol, or the 
result from altered expression of 11ß-HSD-2 in the placenta, as maternal psychopathology 
and stress during pregnancy have been associated with down regulation of 11ß-HSD-2, 
leading to active transfer of maternal cortisol into fetal circulation (41, 42). A promising 
biological mechanism for the fetus’ response to high maternal cortisol is epigenetic 
programming of the HPA axis (43, 44). Candidate genes such as FK506-binding protein 
51 (FKBP51) and the glucocorticoid receptor gene NR3C1 have been associated with HPA 
axis functioning and glucocorticoid sensitivity and susceptibility of psychiatric disorders 
(45-47). Altered methylation of these genes could alter the HPA axis activity in the offspring 
(44). Yet, not all variation can be attributed to these epigenetic findings and thus 
examining of other additional mechanisms is desired.  
 
Strengths and limitations 
Primary strengths of the study are the large population-based sample, the prospective 
nature of the study and the ability to take many confounders into account. Another strength 
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of the current study is the used method of the hair corticosteroid measurements, as 
performed with the state-of-the-art LC-MS/MS based method. A known limitation of hair 
corticosteroid measurement is that over time hormone levels may decrease in parts of the 
hair samples that are most distal from the scalp. However, we used the proximal three cm 
and there is agreement that the wash-out decline occurs only after a time span of 3 to 6 
months (48). Despite the strengths of our study, there are some limitations that need to be 
discussed. We only used self-reported information of maternal psychopathology symptoms 
and stress during pregnancy. It was not feasible to perform diagnostic interviews in such 
a large cohort. In addition, not all dimensions of stress, e.g. work-related stress, were 
measured in the current study, even though we used multiple questionnaires to assess 
stress. Next, women with symptoms of psychopathology and stress during pregnancy 
potentially experienced symptoms of psychopathology and stress over a longer period of 
time after pregnancy, influencing stress levels of the offspring. The current study did not 
correct for postnatal psychopathology and stress and future studies should focus on the 
influence of chronicity of stress. Additionally, no assessment of experienced stressful 
events in the children in the three months before collection of the hair sample was 
available, which could have caused increased stress and thus cortisol levels in the children. 
Finally, selection bias and residual confounding cannot be ruled out, and thus results must 
be interpreted carefully. 
 
Conclusion and future recommendations 
In the current study an association was observed between maternal psychopathology and 
stress during pregnancy and hair cortisone levels in children 6 years of age, suggesting 
alterations in long-term HPA axis activity in children exposed to maternal psychopathology 
and stress during pregnancy. Altered HPA axis functioning may increase susceptibility for 
physical disease and mental health problems in later life (49, 50). Nevertheless, we must 
be careful when interpreting these results and infer causality. The use of hair cortisone as 
a valid biomarker should be further established and future studies should examine whether 
these psychoendocrinological differences between exposed and non-exposed children 
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This thesis discusses several aspects of the use of antidepressants in the perinatal period. 
In Part I of this thesis we evaluated the translation of previous findings concerning 
antidepressant use in the perinatal period into current practice. We reviewed current 
internationally available guidelines and assessed adherence to the Dutch guideline by 
gynecologists and midwives. Additionally, we mapped dispensing patterns of 
antidepressants in the perinatal period throughout the years and examined the influence 
of the introduction of the guideline on dispension patterns. In Part II we outlined the design 
of a randomized controlled trial (RCT) for testing the efficacy and safety of discontinuation 
of antidepressants during pregnancy. We also presented our first results from the 
observational cohort of the Stop or Go trial, which ran parallel to the RCT. Part III focused 
on the influence of (untreated) symptoms of psychopathology during pregnancy on child 
outcomes from a biological perspective. Detailed descriptions on main results and 
shortcomings of the studies were discussed in the previous chapters. This chapter will 
provide a general discussion of all main findings, methodological considerations, 




1. What do internationally available guidelines recommend when it comes to 
treatment of perinatal depression and/or the perinatal use of antidepressants? 
In chapter 3 we reviewed sixteen Clinical Practice Guidelines (CPGs) of which eight were 
perinatal specific. We compared recommendations regarding continuation or withdrawal 
of antidepressants in the perinatal period and preferred treatment options in newly 
depressed patients. Four guidelines advised to continue antidepressants during pregnancy 
and five guidelines did not specifically advise or discourage continuation. For new 
episodes of depression, guidelines agree on psychotherapy as initial treatment for mild to 
moderate depression and antidepressants for severe depression, with a preference for 
sertraline. Paroxetine is not preferred treatment for new episodes but switching 
antidepressants for ongoing treatment is discouraged by three guidelines.  
 
2. Are Dutch gynecologists and midwives aware of the Dutch guideline on 
antidepressant use during pregnancy and do they adhere to this guideline? 
Self-reported familiarity of Dutch gynecologists and midwives with the guideline was 
92.7%. However, current practice and advice given to patients by caregivers differed 
substantially, both between gynecologists and midwives as well as within both professions. 
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Overall guideline adherence was 13.9%. We examined what caregiver characteristics 
influenced guideline adherence and found only profession to be of importance; 
gynecologists reported a higher adherence rate to the guideline (OR 2.1, 95%CI 1.02-
4.33) than midwives.  
 
3. In what way have Dutch perinatal dispensing patterns of antidepressants 
developed over time and to what extent was the introduction of the guideline of 
influence? 
From 1999 to 2014 a persistent significant rise of dispensing rates of selective serotonin 
reuptake inhibitors (SSRIs) at preconception, in pregnancy and childbed was observed. 
The largest increase was observed during pregnancy: in 1999/2000 0.8% of pregnant 
women were using SSRIs compared to 2.1% of pregnant women in 2013/2014. 
Additionally, we observed a substantial change of practice in terms of the SSRI used. Over 
time, the relative number of paroxetine dispenses decreased steeply (from 58.5% to 
27.6%), and especially citalopram and sertraline showed an increase. With time, less 
women using SSRIs in the year before pregnancy discontinued medication during 
pregnancy (from 81% in 1999/2000 to 54% after 2012). None of these patterns seemed 
affected by the introduction of the Dutch guideline in 2012. 
 
4. With what design can we examine the efficacy and safety of discontinuation of 
antidepressants during pregnancy? 
Despite considerable scientific efforts to obtain evidence on the risks and benefits of 
antidepressant use in the perinatal period, the evidence available is unequivocal. 
Published studies are usually retrospective, arguably selective, and in part inevitable due 
to the ethical demands of research in this context. For a better evidence-based decision 
on antidepressant continuation or discontinuation during pregnancy, results from 
randomized controlled trials (RCT) are needed. In chapter 6 we therefore gave a detailed 
description on the first RCT internationally performed. The Stop or Go study is a pragmatic 
multi-centre non-inferiority RCT in which women were randomly allocated into two groups: 
STOP or GO. Women assigned to discontinuation of antidepressants (STOP) were referred 
to a physician for guided tapering of their antidepressants. Trained psychologists provided 
preventive cognitive therapy in the discontinuation arm. Women assigned to continuation 
of antidepressants (GO) obtained usual care. Both groups received regular assessments 





5. Which women with antidepressant use during pregnancy have recurrence of 
depression in the perinatal period? 
From a clinical perspective, it is valuable to be able to recognize which pregnant women 
using antidepressants are at risk for recurrence of depression. With this knowledge, 
clinicians will be able to inform patients about their potential risks and arrange additional 
guidance when necessary, thereby promoting individualized patient-centered care and 
potentially avoiding negative effects on the offspring. In chapter 7 we analyzed 85 
pregnant women with antidepressant use at start of their pregnancy and a history of 
depression. Eight women (9.4%) experienced a recurrence of depression; two during 
pregnancy and six in the first 12 weeks postpartum. All women with recurrence of 
depression had first onset of depression during childhood or adolescence and had at least 
2 psychiatric co-morbidities. Due to the limited number of events we chose to identify 
predictors for recurrence univariably. This yielded associations for recurrence with 
depressive symptoms around 16 weeks of pregnancy (OR 1.28, 95%CI 1.08-1.52), number 
of psychiatric co-morbidities (OR 1.89, 95%CI 1.16-3.09) and duration of antidepressant 
use (OR 1.01, 95%CI 1.00-1.02). 
 
6. Is maternal psychopathology and stress during pregnancy associated with long-
term HPA axis activity in the offspring? 
In chapter 8 we described the results from our study within the population-based 
Generation R cohort. Our results suggest that maternal psychopathology and stress during 
pregnancy are associated with long-term HPA axis activity of the offspring. We used both 
hair cortisol and cortisone to measure HPA axis activity and observed higher hair cortisone 
levels in children exposed to intrauterine psychopathology (adjusted B = 0.18, 95%CI 
0.05;0.31, p-value < 0.01) and stress (adjusted B = 0.51, 95%CI 0.23;0.79, p-value < 
0.01). No association with offspring hair cortisol was found.  
 
 
PART I: PERINATAL USE OF ANTIDEPRESSANTS 
In this thesis we demonstrated that internationally available Clinical Practice Guidelines 
(CPGs) had general consensus on what is considered ‘best clinical practice’, but differed 
in other recommendations throughout the perinatal period. While CPGs are developed to 
facilitate decision-making and optimize patient-care (1), some of the reviewed CPGs gave 
scarce direction for treatment management. Overall, the guidelines have good quality (2), 
but most CPGs were not specifically developed for pregnant women. In our review, only 
eight guidelines were perinatal specific. For our review, we did not include Clinical 
Consensus Statements (CSSs) because they are not developed in accordance with the 
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same quality criteria as CPGs. CSSs reflect the expert views of a panel of individuals who 
are well versed on the topic of interest while carefully examining and discussing the 
scientific data available. Recommendations by CSSs might differ from those given in 
CPGs. In clinical practice, CSSs and other guiding documents are frequently used instead 
of the formal guidelines and might contain a higher level of detail.  
 Adherence to the Dutch guideline was examined in more detail with a cross-
sectional study amongst gynecologists and midwives. Although self-reported familiarity 
with the guideline was high (92.7%), self-reported guideline adherence was low (13.9%). 
Non-adherence can result in conflicting advice to patients from different caregivers, 
creating a potentially difficult situation for vulnerable women. Especially since the same 
variation in advice was reported previously in a survey amongst Dutch General 
Practitioners (GPs) (3). Compared to adherence to guidelines on not pregnancy-related 
topics, our observed adherence rate was substantially less (4). However, previous research 
examining adherence amongst midwives to obstetric guidelines showed equally low 
adherence rates (5, 6). In our study, professional-related characteristics and perceptions 
did not explain a significant part of variance in non-adherence. A limitation of our study is 
that often-reported barriers for guideline non-adherence, such as patient preference or 
professional’s personal experience, were not assessed in this study (4, 7). Another 
limitation is the size and representativeness of our study population, since it was not 
possible to send an invitation to all caregivers individually.  
 In our last chapter of part I, we presented population-based information on 
antidepressant dispensing and dispensing patterns related to the pregnancy phases over 
16 years (1999-2015) in the Netherlands. We observed a general trend of increased SSRI 
use in the year before pregnancy, during pregnancy and in the year following pregnancy, 
a substantial change of practice with regard to continuation over time, and a changed 
pattern in terms of particular SSRI used. Prescription rates before, during and after 
pregnancy in the Netherlands were comparable to Denmark and Italy, but prescription 
rates in the UK and the USA were considerably higher (9.6% in the UK in the year before 
pregnancy and 13.4% in the USA during pregnancy) (8, 9). A trend towards more 
continuation of antidepressants into pregnancy is observed over the years, without an 
obvious change in trend after introduction of the Dutch guideline, which recommends 
continuation of SSRIs if women are stable on this medication and psychiatric indication is 
correct. The size and composition of the pharmo-perined cohort is a major strength of this 
study, but we also encountered some limitations. Exact timing of drug dispensing was 
unknown, making it impossible to analyze subtler discontinuation patterns. A more general 
limitation when using an administrative dispensing database is the relation of dispensing 
to actual use. There might have been an overestimation of use if women do not adhere to 
the prescribed regimen.  
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PART II: THE STOP OR GO TRIAL 
The Stop or Go trial was both a randomized controlled trial (RCT) and an observational 
cohort trial. In chapter 6 we therefore gave a detailed description on the first RCT 
internationally performed on continuing or tapering antidepressant medication during 
pregnancy in mentally stable women with a history of depression. Previously, only 
observational studies examining discontinuation of antidepressants during pregnancy have 
been performed, as many regarded a RCT not medically-ethically justified (10, 11). Results 
of the Stop or Go RCT are not published in this thesis, as the study is still ongoing. 
 In chapter 7, we presented our first Stop or Go observational cohort data. In this 
study we followed 85 women with a history of depression and antidepressant use at start 
of the study. Eight women (9.4%) experienced a recurrence of depression. Our overall 
recurrence rate is remarkably lower than two previous studies reporting recurrence rates 
of depression amongst women with antidepressant use during pregnancy (43% and 16%) 
(10, 11). Differences in recurrence rates may be due to differences in the study 
populations, as mean number of previous depressive episodes was lower in our 
population and number of previous episodes in the general adult population has been 
found to be one of the strongest predictors for recurrence of depression (12). Although 
six out of eight women with recurrence of depression received psychiatric health care in 
the perinatal period, two women did not receive, or only very limited, additional 
psychiatric health care, indicating that they did not receive treatment for their recurrence 
of depression. This is unwanted as a review of 23 longitudinal studies found that 38% of 
mothers with postpartum depression (PPD) continued to have major depression during 
their child’s first year of life and even beyond, with a previous history of depression as a 
predictor for a chronic course of PPD (13). The impact of maternal postpartum depression 
on the developing infant is by now well established (14). However, compared to health 
care seeking behavior among pregnant women with mental illness in the US, the 
percentage of women receiving care in the current study was high (15, 16).  
To identify risk factors for recurrence of depression, we use univariable logistic 
regression, resulting in three predictors for recurrence of depression; EPDS score at 16 
weeks of pregnancy, number of psychiatric co-morbidities and duration of antidepressant 
use. At baseline, five cases already had an EPDS score above cut-off (17), although they 
did not fulfill the criteria yet for depressive disorder according to the SCID. The EPDS 
consists of ten questions and can thus be easily assessed in early pregnancy. Guidelines 
encouraging routine screening for perinatal depression have been available for over a 
decade (18). Previous validation research of the EPDS found that a cutoff value of 11 in 
the first trimester and that of 10 in the second and third trimesters gave the most adequate 
combination of sensitivity, specificity, and positive predictive value (17). Methodologically 
the major limitation of our study was the number of recurrences during follow-up. For an 
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extensive prediction model with several predictors, more events would need to have taken 
place. Due to the limited number of events we chose to identify predictors for recurrence 
univariably. However, we might have missed other important risk factors and results must 
be interpreted with caution.  
 
 
PART III: IMPACT OF MENTAL DISORDERS DURING PREGNANCY ON 
THE OFFSPRING 
In the final part of this thesis our focus was not on treatment of mental illness during 
pregnancy but on (untreated) symptoms of mental illness during pregnancy and associated 
risks for the offspring. Previous research has found an array of adverse birth outcomes 
(19-22) and several underlying pathways have been proposed (23-25). In chapter 8 we 
examined the effect of intrauterine exposure to maternal psychopathology and stress on 
long-term HPA axis functioning in the offspring. We observed that children exposed to 
intrauterine symptoms of psychopathology and stress had increased hair cortisone levels. 
Overall, hair cortisone levels have not often been investigated, but interest in hair cortisone 
as additional biomarker to hair cortisol has recently increased. For example, one previous 
prospective cohort study has examined the influence of stress in children on hair cortisone 
levels (26). Hair cortisone levels of 168 elementary school girls (5 to 10 years old) were 
measured and child-reported stress was obtained through questionnaires. Positive 
associations were observed between hair cortisone and stressful events over the past 6 
months. Another recent study among 62 pregnant women evaluated the association 
between symptoms of depression, somatization and stress and hair cortisol and cortisone 
levels (27) and observed stronger associations with hair cortisone than with hair cortisol. 
In our study, we did not find associations between maternal psychopathology and stress 
during pregnancy and offspring hair cortisol levels. Previous studies did find increased 
salivary cortisol levels in children with intrauterine exposure to maternal psychopathology 
(28, 29). This discrepancy could, among others, originate from the difference in 
measurement method of cortisol (saliva versus hair). Cortisol assessed from hair samples 
is a more stable long-term stress indicator, not dependent on stressors during sampling. 
Possibly, intrauterine exposure to maternal psychopathology and stress influences the 
immediate stress response but not long-term (basal) cortisol levels. The most apparent 
limitation of our study is the measurement method of maternal psychopathology and stress. 
We only used self-reported information of maternal psychopathology symptoms and stress 
during pregnancy. It was not feasible to perform diagnostic interviews in such a large 
study. In addition, not all dimensions of stress, e.g. work-related stress, were measured in 
the current study, even though we used multiple questionnaires to assess stress. 
General discussion 
 161 
CLINICAL AND RESEARCH IMPLICATIONS 
The studies in this thesis provide the following clinical and research implications: 
o Review of the internationally available CPGs outlines the need for up-to-date and 
perinatal-specific CPGs to help clinicians and patients in decision-making. It is 
challenging to develop these CPGs because evidence-based medicine, 
personalized medicine and legal liabilities need to be balanced. This overview 
can serve as a clear starting point for further development of internationally 
congruent guidelines to improve consistent patient guidance independent of 
country and setting. The review also helps to identify gaps in current evidence, 
since guidelines do not disclose recommendations on emerging clinical 
questions. For example, none of the guidelines discusses treatment options for 
patients with current depressive symptomatology despite antidepressant use. 
Future research should focus on these gaps and on finding answers to emerging 
clinical questions. 
o Although guideline familiarity is high, adherence amongst both Dutch 
gynecologists and midwives is low. This can result in treatment management 
recommendations that are not in line with evidence based clinical guidelines. 
Also, patients can encounter conflicting advice from different caregivers, which 
is unwanted in this vulnerable population. Qualitative research should explore 
reasons for guideline non-adherence and stimulate further implementation of 
the guideline, and thus more congruent care, in daily clinical practice. 
Additionally, the Dutch guideline has to be reviewed critically as the 
recommendations differ from recommendations of CPGs from other countries. 
Meanwhile, more conclusive underlying evidence has to emerge on harms and 
benefits of antidepressants during pregnancy in order to improve internationally 
available perinatal specific guidelines. Prospective (observational) research has 
to be initiated collecting data on not only antidepressant use but also on 
psychiatric history and current psychiatric features in order to adjust for 
confounders.  
o From 1999 to 2015 there has been a substantial and significant increase in use 
of antidepressants in the perinatal period. Additionally, a change towards 
continuation rather than quitting antidepressant use if women get pregnant is 
observed. Despite a substantial shift in drug preference, paroxetine is still most 
commonly used during the perinatal period in the Netherlands, while in the 
Nordic countries, paroxetine is the least prescribed SSRI during pregnancy. 
Future research should elicit whether this implicit ‘vote’ in favor of 
antidepressant treatment is justified and if so, what these justifiable factors are. 
We would have to examine whether this increase in antidepressant treatment 
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has accomplished a decrease in perinatal psychiatric disease. Also, 
effectiveness of antidepressant treatment compared to non-pharmacological 
treatment has to be investigated in prospective settings. Differences in 
prescription rates between countries should be investigated based on 
population-based prescription rates over the past decades, as well as their 
connection to local policy and adherence to locally available guidelines. 
o Pregnant women with antidepressant use risk recurrence of depression in the 
perinatal period. Three risk factors for recurrence of depression that are easily 
assessed by the clinicians guiding women in their pregnancy, such as midwifes, 
obstetricians, psychiatrists and general practitioners, are EPDS score in early 
pregnancy, number of psychiatric co-morbidities and duration of antidepressant 
use. Clinicians should use the EPDS and can use the validated cut-off scores to 
initiate immediate additional treatment, to prevent recurrence but also to 
decrease symptoms of depression and possibly anxiety or stress, which can 
negatively affect child outcomes. Clinicians without training in mental health 
care, such as midwifes and obstetricians, should refer their patients to a 
specialized health care professional, such as a psychiatrist or psychologist, 
preferable with extensive knowledge on the perinatal period. The same applies 
for assessing the presence of psychiatric co-morbidities; when co-morbidities 
are present, the clinician should discuss additional referral and treatment 
targeting these co-morbidities with the client. No effect of discontinuation of 
antidepressants on risk of recurrence was observed and this treatment option 
should therefore not be ruled out. Especially as alternative treatments, such as 
preventive cognitive therapy, could be as efficient as continuation of 
antidepressants. Future research has to extend knowledge on risk factors (for 
example social environment and partner stability) for recurrence of depression 
in the perinatal period and examine (preventive) non-pharmacological treatment 
methods.  
o Children with intrauterine exposure to maternal psychopathology and stress 
have increased levels of hair cortisone at 6 years of age, suggesting alterations 
in long-term HPA axis activity. Altered HPA axis functioning may increase 
susceptibility for physical disease and mental health problems in later life. 
Before inferring causality, future research should further establish hair cortisone 
as a valid biomarker and our findings need to be confirmed by studies with 







An increase in use of antidepressants during the perinatal period has been observed, 
while risk and benefits have not yet been established. International guidelines on this topic 
are largely incomplete and often contradictory. Additionally, adherence to the guidelines 
has been discovered to be low, resulting in potentially unwanted variation in daily practice. 
Regardless of antidepressant management, women with antidepressant use at start of their 
pregnancy are at risk for recurrence of depression in the perinatal period, especially if 
symptoms of depression (as measured with the EPDS) are present in early pregnancy and 
if women have psychiatric co-morbidities. Clinicians should evaluate risk of recurrence in 
this population in early pregnancy and act accordingly, as untreated symptoms can lead 
to adverse outcomes in both the mother and the offspring, such as long-term alteration of 
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Mental illness during the perinatal period is common and can affect both the mother and 
her unborn child. Especially perinatal depression, defined as depression arising in the 
period from conception to the end of the first postnatal year, is common, affecting up to 
12% of pregnant women. To avoid adverse outcomes and to decrease burden, prevention 
and management of depression in the perinatal period is of importance. An increasingly 
used treatment method is the administration of antidepressant medication. In chapter 2 
we provided a general introduction on the history and current use of antidepressants. 
Although treatment with antidepressant medication in the perinatal period has been under 
debate, as conflicting results on the safety and efficacy of antidepressants during 
pregnancy have been reported, perinatal usage has been increasing steadily.  
 
In chapter 3 we evaluated how international guidelines have incorporated current 
knowledge in their recommendations with regard to treatment of perinatal depression with 
antidepressants. To retrieve all relevant guidelines, we conducted an extensive search in 
multiple databases and included 16 Clinical Practice Guidelines originating from 12 
countries. Eight guidelines were perinatal specific and eight were general guidelines. 
During pregnancy, four guidelines advise to continue antidepressants, while there is a lack 
of evidence supporting this recommendation. Five guidelines do not specifically advise or 
discourage continuation. For new episodes, guidelines agree on psychotherapy as initial 
treatment for mild to moderate depression and antidepressants for severe depression, with 
a preference for sertraline. Paroxetine is not preferred treatment for new episodes but 
switching antidepressants for ongoing treatment is discouraged. If mothers use 
antidepressants, observation of the neonate is generally recommended and breastfeeding 
encouraged. Overall, the guidelines have good quality, but most were not specifically 
developed for pregnant women and contained limited information on the measures of 
implementation and audit of the proposed measures. We recommend development of up-
to-date and perinatal-specific guidelines to help clinicians and patients in decision-making.  
 
Chapter 4 provides the results of a cross-sectional study among gynecologists and 
midwives regarding adherence to the Dutch guideline on antidepressant use during 
pregnancy. An online survey was developed, consisting mainly of multiple-choice 
questions addressing guideline familiarity and current practice of the respondent. A total 
of 178 gynecologists and 139 midwives responded. Overall familiarity with the Dutch 
guideline was 92.7%. However, current practice and advice given to patients by caregivers 
differed substantially, both between gynecologists and midwives as well as within both 
professions. Overall guideline adherence was 13.9%. We examined whether caregiver 




caregiver profession was associated with guideline adherence, with gynecologists having 
a higher adherence rate (OR 2.10, 95%CI 1.02–4.33) than midwives. Further 
implementation of the recommendations as given in the guideline should be stimulated as 
this can prevent unwanted practice. Additional research is needed to examine how 
gynecologists and midwives can be facilitated to follow the recommendations of the 
clinical guideline on antidepressant use during pregnancy.  
 
In chapter 5 we examined perinatal dispensing patterns of selective serotonin reuptake 
inhibitors (SSRIs) over time and the role of the Dutch guideline in this regard. We 
identified a 16-year cohort of 153,952 Dutch pregnancies with a delivery date between 
January 1999 and December 2014. Data included exposure to SSRIs related to phases of 
pregnancy (preconception, pregnancy and delivery, post-delivery). 
A persistent significant rise of dispensing rates at preconception, in pregnancy and 
childbed was observed, with the largest increase during pregnancy (from 0.8% in 
1999/2000 to 2.1% in 2013/2014, x2 for trend=141.735, p<0.001). A substantial 
change of practice in terms of the SSRI used (less paroxetine) and the policy towards 
continuation into pregnancy (more continuation over time) was visible. Concomitant use 
of psycholeptics halved the probability of continuation of SSRI use during pregnancy (OR 
0.50, 95%CI 0.43-0.55, p<0.01). Given that evidence on safety so far is inconclusive, 
future research should focus on effective alternatives for the use of SSRIs in pregnancy 
and on updated guidelines for patient-tailored advice. 
 
In chapter 6 we outline the protocol of the Stop or Go study: a pragmatic multicenter non-
inferiority randomized controlled trial. As the use of antidepressants during pregnancy is 
still controversial, there is an urgent need among patient and professionals for evidence 
from randomized studies to make rational decision regarding continuation or tapering of 
antidepressants during pregnancy, as no such studies exist so far. In the Stop or Go study, 
pregnant women with a gestational age of less than 16 weeks who use SSRIs or serotonin 
noradrenalin reuptake inhibitors (SNRIs) without clinically relevant depressive symptoms 
are included. Women allocated to the intervention group will receive preventive cognitive 
therapy with gradual, guided discontinuation of antidepressants under medical 
management (STOP). Women in the control group will continue the use of antidepressants 
(GO). Primary outcome of the trial is (cumulative) incidence of relapse or recurrence of 
maternal depressive disorder (as assessed by the Structured Clinical Interview for DSM 
disorders) during pregnancy and up to three months postpartum. Secondary outcomes 
include continuous outcomes such as symptoms of depression and anxiety. Additionally, 




In chapter 7, we report the first results of the prospective observational Stop or Go cohort 
study. The study presented data on a cohort of pregnant women with antidepressant use 
at start of their pregnancy and a history of depressive disorder. Women were followed 
throughout pregnancy and up to three months postpartum and assessed for recurrence of 
depression. Of the 85 women included in the study, eight women experienced recurrence 
of depression of whom two during pregnancy and six in the first weeks after childbirth. 
Characteristics of these women are described in detail in the chapter. Three predictors for 
recurrence of depression were identified that could be easily assessed by treating 
clinicians in daily practice. A higher Edinburgh Postnatal Depression Scale (EPDS) score 
in early pregnancy, a higher number of psychiatric co-morbidities, such as anxiety 
disorders, and a longer duration of antidepressant use were associated with a higher risk 
of recurrence of depression. Previous research of the EPDS found that a cutoff value of 11 
in the first trimester and that of 10 in the second and third trimester gave the most adequate 
combination of sensitivity, specificity, and positive predictive value. Clinicians can use 
these cut-off scores to initiate immediate additional treatment. No effect of discontinuation 
of antidepressants on risk of recurrence was observed. This result should be interpreted 
with caution, as numbers were small. Still, this result could indicate discontinuation of 
antidepressants during pregnancy is feasible. 
 
In chapter 8 we examined the influence of (untreated) symptoms of psychopathology and 
stress during pregnancy on child outcomes from a biological perspective. The study was 
part of the population-based Generation R Study, a prospective population-based cohort 
from fetal life onwards. We examined the relation of perinatal maternal symptoms of 
psychopathology and stress on the one hand with offspring HPA axis activity at 6 years on 
the other hand, as measured by hair cortisol and cortisone concentrations in 2,546 
children. We found that maternal symptoms of psychopathology and stress during 
pregnancy were associated with increased hair cortisone levels in children 6 years of age. 
These results suggest alterations in long-term HPA axis activity in children exposed to 
maternal psychopathology and stress during pregnancy. Altered HPA axis functioning may 
increase susceptibility for physical disease and mental health problems in later life. 
Nevertheless, we must be careful when interpreting these results and infer causality. The 
use of hair cortisone as a valid biomarker should be further established and our findings 
need to be confirmed by studies with other outcome measures related to increased HPA 
axis activity.  
 
Main findings and conclusions of this thesis and methodological considerations are 
reported in chapter 9. Afterwards, we discussed implications of current findings and 




perinatal-specific guidelines and adherence to these guidelines has to be increased. 
Screening for risk factors for recurrence of depression has to be incorporated in 
guidelines and clinical practice. Meanwhile, research should advance in examining effects 
of antidepressants, but also of untreated psychiatric symptoms, on child functioning, both 
short- and long-term. Alternative treatment options have to be validated and implemented 














































































































Psychische aandoeningen tijdens de perinatal periode komen vaak voor en kunnen zowel 
de moeder als haar ongeboren kind beïnvloeden. Vooral perinatal depressie, 
gedefinieerd als depressie die optreedt in de periode vanaf de conceptie tot het einde 
van het eerste postnatale jaar, komt vaak voor en treft tot 12% van de zwangere vrouwen. 
Om nadelige resultaten te voorkomen en de belasting te verminderen, is preventie en 
behandeling van depressie in de perinatale periode van belang. Een steeds vaker 
gebruikte behandelmethode is het toedienen van antidepressiva. In hoofdstuk 2 hebben 
we een algemene inleiding gegeven over de geschiedenis en het huidige gebruik van 
antidepressiva. Hoewel tegenstrijdige resultaten over de veiligheid en werkzaamheid van 
antidepressiva tijdens de zwangerschap zijn gemeld is het perinatale gebruik gestaag 
toegenomen.  
 
In hoofdstuk 3 hebben we onderzocht hoe internationale richtlijnen de huidige kennis 
hebben verwerkt in hun aanbevelingen met betrekking tot de behandeling van perinatale 
depressie met antidepressiva. Om alle relevante richtlijnen op te halen, hebben we een 
uitgebreide zoekactie uitgevoerd in meerdere databases en hebben we 16 klinische 
richtlijnen opgenomen uit 12 landen. Acht richtlijnen waren specifiek voor de perinatale 
periode en acht waren algemene richtlijnen. Tijdens de zwangerschap adviseren vier 
richtlijnen om antidepressiva te continueren, terwijl er een gebrek aan bewijs is om deze 
aanbeveling te ondersteunen. Vijf richtlijnen adviseren niet specifiek om te continueren 
of ontmoedigen dit zelfs. Richtlijnen zijn het eens over het aanbieden van psychotherapie 
als eerste behandeling bij het nieuw optreden van milde tot matige depressie en het 
aanbieden van antidepressiva voor ernstige depressie, bij voorkeur sertraline. Bij een 
nieuwe depressie heeft paroxetine niet de voorkeur, maar het wisselen van antidepressiva 
voor een doorlopende behandeling wordt afgeraden. Als moeder antidepressiva 
gebruiken, wordt observatie van de pasgeborene over het algemeen aanbevolen en wordt 
het geven van borstvoeding aangemoedigd. Over het algemeen zijn de richtlijnen van 
goede kwaliteit, maar de meesten zijn niet specifiek ontwikkeld voor zwangere vrouwen 
en bevatten beperkte informatie over implementatie en het nazien van de voorgestelde 
maatregelen. We raden aan om up-to-date richtlijnen te ontwikkelen specifiek voor de 
perinatal periode om clinici en patiënten te helpen bij het nemen van beslissingen.  
 
Hoofdstuk 4 geeft de resultaten van een cross-sectionele studie onder gynaecologen en 
verloskundigen met betrekking tot het naleven van de Nederlandse richtlijn over 
antidepressiva gebruik tijdens de zwangerschap. Er was een online enquête ontwikkeld, 
die voornamelijk bestond uit meerkeuzevragen over de bekendheid van de richtlijn en de 
huidige praktijkvoering van de respondent. Er hebben in totaal 178 gynaecologen en 139 
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verloskundigen gereageerd. De bekendheid met de Nederlandse richtlijn was 92.7%. 
Huidige praktijkvoering en adviezen aan patiënten door de zorgverleners verschilden 
echter aanzienlijk, zowel tussen gynaecologen en verloskundigen als binnen beide 
beroepsgroepen. Algehele naleving van de richtlijn was 13.9%. We onderzochten of 
kenmerken van de zorgverlener geassocieerd waren met het naleven van de richtlijn en 
vonden dat alleen het beroep van de zorgverlener geassocieerd was met het naleven van 
de richtlijn, waarbij gynaecologen deze vaker naleefden (OR 2.10, 95%CI 1.02-4.33) dan 
verloskundigen. Verdere implementatie van de aanbevelingen in de richtlijn moet worden 
gestimuleerd, omdat dit ongewilde praktijkvoering kan voorkomen. Aanvullend onderzoek 
is nodig om te onderzoeken hoe gynaecologen en verloskundigen gefaciliteerd kunnen 
worden in het volgen van de aanbevelingen van de klinische richtlijn over 
antidepressivagebruik tijdens de zwangerschap.  
 
In hoofdstuk 5 onderzochten we perinatale afgiftepatronen van selectieve serotonine 
heropname remmers (SSRI’s) door de jaren heen en de invloed van de Nederlandse 
richtlijn hierop. We identificeerden een 16-jarig cohort van 153.952 Nederlandse 
zwangerschappen met een bevallingsdatum tussen januari 1999 en december 2014. 
Gegevens omvatten blootstelling aan SSRI’s gerelateerd aan de verschillende fasen van 
zwangerschap (preconceptioneel, zwangerschap en bevalling en na de bevalling).  
We namen een aanhoudende significantie stijging waar in de afgiftepatronen tijdens 
preconceptie, zwangerschap en bevalling, met de grootste stijging tijdens de 
zwangerschap (van 0.8% in 1999/2000 tot 2.1% in 2013/2014, x2 voor trend = 141.735, 
p<0.001). Een aanzienlijke verandering in de soort SSRI’s die werden gebruikt was 
zichtbaar (minder paroxetine) en een verandering met betrekking tot het continueren 
tijdens de zwangerschap (meer continuatie door de jaren heen). Gelijktijdig gebruik van 
psycholeptica halveerde de kans op continuatie van SSRI gebruik tijdens de zwangerschap 
(OR 0.50, 95%CI 0.43-0.55, p<0.01). Aangezien bewijs over de veiligheid tot nu toe 
nog tegenstrijdig is, moet toekomstig onderzoek zich richten op effectieve alternatieven 
voor het gebruik van SSRI’s tijdens de zwangerschap en op bijgewerkte richtlijnen voor 
advies op maat. 
 
In hoofdstuk 6 schetsen we het protocol van de Stop or Go studie: een pragmatische, 
gerandomiseerd, multicenter, niet-inferioriteitsstudie. Aangezien het gebruik van 
antidepressiva tijdens de zwangerschap nog steeds controversieel is, is er bij patiënten 
en professionals een dringende behoefte aan bewijs uit gerandomiseerde onderzoeken 
om rationeel te beslissen over voortzetten of afbouwen van antidepressiva tijdens de 
zwangerschap, omdat dergelijke studies tot nu toe niet bestaan. In de Stop or Go studie 
worden zwangere vrouwen met een zwangerschapsduur van minder dan 16 weken die 
Nederlandse samenvatting 
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een SSRI of een serotonine noradrenaline heropnameremmer (SNRI) gebruiken zonder 
klinisch relevante depressieve symptomen geïncludeerd. Vrouwen in de interventiegroep 
ontvangen preventieve cognitieve therapie met geleidelijke, medisch begeleide 
stopzetting van antidepressiva (STOP). Vrouwen in de controlegroep blijven de 
antidepressiva gebruiken (GO). Primaire uitkomst van de studie is (cumulatieve) incidentie 
van terugval of recidief van depressieve stoornis (zoals beoordeeld door het 
gestructureerde klinische interview voor DSM-stoornissen) tijdens de zwangerschap en tot 
drie maanden na de bevalling. Secundaire uitkomsten omvatten continue uitkomsten zoals 
symptomen van depressie en angst. Aanvullend worden kind uitkomsten gemeten. 
 
In hoofdstuk 7 rapporteren we de eerste resultaten van de prospectieve observationele 
Stop or Go cohortstudie. De studie presenteerde gegevens over een cohort van zwangere 
vrouwen met antidepressivumgebruik aan het begin van hun zwangerschap en een 
depressieve stoornis in de voorgeschiedenis. Vrouwen werden gevolgd gedurende de 
zwangerschap en tot drie maanden na de bevalling en beoordeeld op recidief van 
depressie. Van de 85 vrouwen die deelnamen aan de studie, ervoeren acht vrouwen een 
recidief van depressie, van wie twee tijdens de zwangerschap en zes in de eerste weken 
na de bevalling. De kenmerken van deze vrouwen worden in detail beschreven in het 
hoofdstuk. Drie voorspellers voor recidief van depressie werden geïdentificeerd die 
gemakkelijk gemeten konden worden door clinici in de dagelijkse praktijkvoering. Een 
hogere Edinburgh Postnatal Depression Scale (EPDS) score in de vroege zwangerschap, 
een hoger aantal psychiatrische comorbiditeiten, zoals angststoornissen, en een langere 
duur van antidepressiva gebruik waren geassocieerd met een hoger risico op recidief van 
depressie. Eerder onderzoek van de EPDS wees uit dat een afkapwaarde van 11 in het 
eerste trimester en die van 10 in het tweede en derde trimester de meest adequate 
combinatie van gevoeligheid, specificiteit en positief voorspellende waarde gaf. Artsen 
kunnen deze afkapwaarden gebruiken om een onmiddellijke aanvullende behandeling te 
starten. Er werd geen effect gevonden van afbouw van antidepressiva met op risico van 
recidief. Dit resultaat moet voorzichtig geïnterpreteerd worden, aangezien de aantallen in 
deze studie klein waren. Toch zou het resultaat er op kunnen wijzen dat het staken van 
antidepressiva tijdens de zwangerschap mogelijk is. 
 
In hoofdstuk 8 onderzochten we de invloed van (onbehandelde) symptomen van 
psychopathologie en stress tijdens de zwangerschap op kind uitkomsten vanuit een 
biologisch perspectief. De studie was onderdeel van de populatie gebaseerde Generation 
R Study, een prospectieve populatie gebaseerd cohort vanaf het foetale leven. We 
onderzochten de relatie tussen perinatale maternale symptomen van psychopathologie en 
stress enerzijds en HPA-as activiteit in de nakomelingen op 6-jarige leeftijd anderzijds, 
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gemeten door cortisol en cortison concentraties in het haar, in 2.546 kinderen. We 
vonden dat maternale symptomen van psychopathologie en stress tijdens de 
zwangerschap geassocieerd waren met verhoogde haar cortison concentraties bij 
kinderen van 6 jaar oud. Deze resultaten suggereren veranderingen in de HPA-as activiteit 
op lange termijn bij kinderen die worden blootgesteld aan maternale psychopathologie 
en stress tijdens de zwangerschap. Veranderde werking van de HPA-as kan de 
gevoeligheid voor fysieke ziekte en geestelijke gezondheidsproblemen op latere leeftijd 
vergroten. Niettemin moeten we voorzichtig zijn bij het interpreteren van deze resultaten 
en het afleiden van causaliteit. Het gebruik van haar cortison als valide biomarker moet 
verder worden vastgesteld en onze bevindingen moeten worden bevestigd door studies 
met andere uitkomstmaten die verband houden met verhoogde HPA-as activiteit. 
 
De belangrijkste bevindingen en conclusies van dit proefschrift en de methodologische 
overwegingen worden gerapporteerd in hoofdstuk 9. Nadien bespraken we de 
implicaties van de huidige bevindingen en gaven aanbevelingen voor toekomstig 
onderzoek. We concluderen dat er behoefte is aan up-to-date richtlijnen specifiek voor de 
perinatale periode en dat de naleving van deze richtlijnen moet worden verhoogd. 
Screening op risicofactoren voor recidief van depressie moet worden opgenomen in 
richtlijnen en in huidige praktijkvoering. Ondertussen moet verder onderzoek worden 
uitgevoerd naar de effecten van antidepressiva, maar ook van onbehandelde 
psychiatrische symptomen, op het functioneren van kinderen, zowel op de korte als de 
lange termijn. Alternatieve behandelingsopties moeten worden gevalideerd en 
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Member of the PREGMETHICs expert meeting    2016 
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